Categorization of major IIP.
The term “Interstitial pneumonia” (IP) is used to describe noninfectious, inflammatory lung disorders characterized by the histologic abnormalities with diffuse interstitial fibrosis involving alveolar walls. In contrast to airspace disease typically seen in bacterial pneumonia, IP refers to involvement of the lung parenchyma by varying combination of fibrosis and inflammation [1, 2]. IP is included in the “interstitial lung disease” (ILD), i.e., a heterogenous group of diffuse parenchymal lung disorders, either idiopathic or associated with injurious or inflammatory causes, in which the major site of damage is the lung interstitium [3]. Customarily, the designations IP and ILD are sometimes used interchangeably. To be accurate, however, ILD comprises a broader range of lung diseases which involves the pulmonary interstitium, including drug-induced pneumonitis and eosinophilic pneumonia, etc. Primarily, IP refers to the particular disease entities which belong to idiopathic interstitial pneumonia (IIP) defined by the 2002 and 2012 American Thoracic Society/European Respiratory Society (ATS/ERS) classification [1–4]. IIP was categorized into several forms of IPs, afterward each histopathologic pattern of which has been applied to the ILD associated with underlying diseases as well; the details of these will be described later.
From the pathophysiological perspective, the pulmonary interstitium consists of area with minimal connective tissue matrix between the capillaries and the alveolar space that allows close apposition of gas and blood flow leading to efficient gas exchange. If any injury from a specific exposure of chemicals or proteins, an autoimmune-mediated inflammation, or unknown etiology occurs and persists, the lung may respond to the damage by repairing process with increased interstitial tissue resulting in histological remodeling. Thus, ILDs may cause serious pulmonary dysfunction, which is often associated with substantial morbidity and poor prognosis.
ILD comprises a variety of disorders with diverse backgrounds. A part of ILD has no identifiable underlying cause and is regarded as idiopathic, whereas it is often associated with a specific environmental exposure or with underlying diseases such as connective tissue disease (CTD) [1]. The CTDs are a group of systemic, inflammatory, autoimmune disorder, in which autoimmune-mediated tissue injury leads to multiple organ impairment including respiratory system. Today, IP or ILD is one of the most serious pulmonary complications associated with CTDs, resulting in significant morbidity and mortality [5]. Despite growing, understanding of the details of pathology in IPs, as well as accumulating evidences which support an association between IP with CTD and the presence of autoantibodies, the pathogenesis of CTD-associated IP remains unclear.
During the last years, we have been exploring the possible involvement of adaptive immunity in the pathogenesis of IP associated with CTDs, and we found intriguing evidence which strongly suggests a pivotal role of T cells in triggering the development of pulmonary alveolitis through antigen-driven immune responses in early stage IP [6, 7]. In this chapter, first, we will overview the current concepts of ILD as well as CTD-associated IP, in order to comprehend the whole picture including pathological features. Then, novel findings demonstrated in our recent studies of IP associated with polymyositis/dermatomyositis will be discussed.
ILD, also known as diffuse parenchymal lung disease (DPLD), is a generic term encompassing a broad spectrum of heterogenous lung disorders, either idiopathic or associated with injurious or inflammatory causes, in which the major site of damage is the lung interstitium [1–3]. Because of the nature of DPLD which involves the interstitium, the ILDs share common radiologic, pathologic, and clinical manifestations. Clinically, exertional dyspnea and nonproductive cough are most common manifestations. Bilateral inspiratory fine crackles, most prominent at the lung bases, are usually audible on auscultation. Clubbed fingers characterized by hypertrophy and enlargement of the distal phalanges of the hands are often seen and reported in 30–50% of patients with IPF (idiopathic pulmonary fibrosis; to be mentioned later) [8]. Clinical features suggestive of rheumatic disorders, such as arthralgia, Raynaud’s phenomenon, and skin manifestations, might be observed in the setting of an underlying CTD. The plain chest radiograph shows reduced lung volumes with bilateral reticular or reticulonodular opacities. High-resolution computed tomography (HRCT), which offers better definition of the characteristic details of lung parenchyma, can reveal usually bilateral, peripheral, and basilar predominant abnormalities with reticulonodular infiltrates, often with honeycombing and cystic changes by IP type to be described later. Although chest radiography is less useful than HRCT in the detailed evaluation, it is helpful for evaluating disease distribution and its serial change during patient follow up [8]. Physiologically, the patients demonstrate diminished diffusion capacity (decreased DLco) with usually restrictive impairment in pulmonary function tests.
Figure 1 provides an overview of the classification of ILD, based on the 2002 and 2012 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification statements [1–3]. Briefly, ILDs consist of disorders of known causes (underlying diseases, environmental, or drug related) as well as disorders of unknown causes. The latter include idiopathic interstitial pneumonias (IIPs), granulomatous lung disorders (e.g., sarcoidosis), and other forms of orphan ILD, i.e., lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis/histiocytosis X (PLCH), and eosinophilic pneumonia. Thus, the ILDs comprise a variety of disorders with diverse backgrounds. Whereas a part of ILD has no identifiable underlying cause, often, it is associated with a specific environmental exposure or with underlying CTD [5]. ILDs are classified according to specific clinical, radiological, and histopathological features. The ILDs, however, frequently have similar clinical features. As ILDs are often uneasy to distinguish each other, the updated guidelines in the 2013 ATS/ERS classification statement underlined the importance of multidisciplinary diagnosis (MDD) facilitated by professional experts [2, 3]. Adequate presentation and discussion of clinical and radiological data are essential for an accurate MDD. Among diagnostic modalities, high-resolution computed tomography (HRCT) makes it possible to characterize ILD with great precision. Surgical lung biopsy also remains the gold standard for evaluation of ILD.
Classification of interstitial lung disease. Interstitial lung diseases (ILDs), also termed as diffuse parenchymal lung diseases (DPLDs), consist of disorders of known causes (connective tissue diseases, environmental, or drug related) as well as disorders of unknown cause. The latter include idiopathic interstitial pneumonias (IIPs), granulomatous lung disorders (e.g., sarcoidosis), and other forms of interstitial lung disease (ILD) including lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis/histiocytosis X (PLCH), and eosinophilic pneumonia. The idiopathic interstitial pneumonias (IIPs) are further categorized as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumnia (COP), acute interstitial pneumonia (AIP), respiratory bronchiolitis interstitial lung disease (RB-ILD), or desquamative interstitial pneumonia (DIP). Lymphoid interstitial pneumonia (LIP) is occasionally associated with other disease processes, such as connective tissue diseases or immunosuppression while idiopathic LIP is rare.
As noted above, if ILD is found to have no association with specific causes, such as chemical exposure, underlying systemic diseases, or genetic causes, the disease is classified as “idiopathic interstitial pneumonia” (IIP). IIPs are a heterogenous group of nonneoplastic disorders involving damage to the lung parenchyma with varying patterns of inflammation and fibrosis. The interstitium includes the space between epithelial and endothelial basement membranes and is the primary site of injury in IIPs. Frequently affecting not only the interstitium, but IIPs may also involve the airspace, peripheral airways, and vessels, along with their respective epithelial and endothelial linings [1, 2].
As shown in Figure 1, the IIPs are further categorized into “idiopathic pulmonary fibrosis” (IPF), “nonspecific interstitial pneumonia” (NSIP: further subdivided into cellular and fibrotic NSIP), “cryptogenic organizing pneumonia” (COP), “acute interstitial pneumonia” (AIP), “respiratory bronchiolitis interstitial lung disease” (RB-ILD), or “desquamative interstitial pneumonia” (DIP) [1, 2]. “Lymphoid interstitial pneumonia” (LIP) is occasionally associated with other processes, such as connective tissue diseases or immunosuppression, while idiopathic LIP is rare. Among the IIPs, idiopathic pulmonary fibrosis (IPF) is the most common prototypic IIP. “Usual interstitial pneumonia” (UIP) is the pathologic pattern of lung injury seen in IPF. Categorization of major IIP and corresponding histological patterns defining each entity are shown in Table 1 [2].
Category | Clinical–radiologic–pathologic diagnoses | Associated radiologic and/or pathologic morphologic patterns |
Chronic fibrosing IP | Idiopathic pulmonary fibrosis (IPF) | Usual interstitial pneumonia (UIP) |
Idiopathic nonspecific interstitial pneumonia (NSIP) | Nonspecific interstitial pneumonia (NSIP) | |
Smoking-related IP* | Respiratory bronchiolitis-interstitial lung disease (RB-ILD) | Respiratory bronchiolitis-ILD (RB-ILD) |
Desquamative interstitial pneumonia (DIP) | Desquamative interstitial pneumonia (DIP) | |
Acute/subacute IP | Cryptogenic organizing pneumonia (COP) | Organizing pneumonia (OP) |
Acute interstitial pneumonia (AIP) | Diffuse alveolar damage (DAD) |
Categorization of major IIP.
Desquamative interstitial pneumonia can occasionally occur in nonsmokers.
Definition of abbreviation: IP = interstitial pneumonia.
Adapted from Travis et al. [2].
The ATS/ERS/JRS/ALAT 2011 guidelines for IPF have assigned a primary diagnostic role to HRCT, and the HRCT criteria outlined was the same as those in the revised guideline published in 2015 [8–10]. The diagnosis of IPF should be based on the exclusion of other known causes of ILDs (environmental exposures, drugs, and CTDs) and presence of UIP on HRCT; UIP is characterized on HRCT by the presence of reticular abnormalities with subpleural and basal distribution, honeycombing with or without traction bronchiectasis, and absence of features inconsistent with UIP such as extensive ground-glass opacities, diffuse mosaic attenuation, profuse micronodules, and consolidations. Certain HRCT features predict histopathologic patterns of the different forms of ILD. Table 2 outlines the classification of histological and corresponding radiological patterns defining each entity of IIP, which is also applicable to CTD-associated ILD, to be explained later [5, 11].
Pattern | Histology | CT features |
---|---|---|
UIP | Subpleural and peripheral fibrosis. Temporal and spatial heterogeneity. Scattered fibroblastic foci and honeycombing are key features | Basal, subpleural reticulation and honeycombing; traction bronchiectasis; little, if any, ground-glass attenuation |
NSIP | Uniform interstitial involvement by variable degrees of degrees of fibrosis and inflammation. Honeycombing is rare | Bilateral patchy ground-glass opacities admixed with reticulation and traction bronchiectasis/bronchiolectasis. Little or no honeycombing. Usually, predominantly basal |
OP | Connective tissue plugs within small airways and air spaces (Masson bodies). In its “pure” form, little or no inflammation or fibrosis in the surrounding interstitium | Airspace consolidation, with a predominantly basal/peripheral or peribronchovascular distribution. Bands with air bronchograms and a perilobular pattern can also be seen |
DIP | Extensive macrophage accumulation within the distal air spaces. Mild interstitisal involvement | Patchy ground-glass opacities. Microcystic change can be seen within the ground-glass, Basal, peripheral distribution frequent |
LIP | Bronchiolocentric lymphoid tissue hyperplasia | Ground-glass attenuation is the predominant finding, with thin-walled cysts frequently present. Lung nodules and septal thickening may also be seen |
RB-ILD | Bronchiolocentric macrophage accumulation. Mild bronchiolar fibrosis | Centrilobular nodules, ground glass opacities. Diffuse or upper lung distribution |
DAD | In the acute phase: hyaline membrane, edema. In the organizing phase: airspace and interstitial organization | Acute phase: diffuse ground-glass opacities and consolidation in dependent areas. Organizing phase: reticular pattern, traction bronchiectasis and architectural distortion |
Classification of histological and radiological patterns for IP.
Abbreviation: DIP, desquamative interstitial pneumonia; NSIP, non-specific interstitial pneumonia; UIP, usual interstitial pneumonia; OP, organizing pneumonia; DAD, diffuse alveolar damage; RB-ILD, respiratory bronchiolitis interstitial lung disease; LIP, lymphocytic interstitial pneumonia.
Adapted from de Lauretis et al. [11].
The connective tissue disease (CTD) is a systemic, inflammatory, autoimmune disorder characterized by immune-mediated multiple organ dysfunction. The category of CTD includes a variety of diseases: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (Scleroderma, SSc), polymyositis/dermatomyositis (PM/DM), and a group of vasculitides. The CTD-related disorders such as Sjögren’s syndrome (SS), mixed connective tissue disease (MCTD), etc., are also captured under the extended umbrella of CTD, as they share similar features. Involvement of the respiratory system occurs in those diseases and may be often major contributor to significant morbidity and mortality [5]. The clinical presentation is variable, ranging from cough, dyspnea, pleuritic pain to abnormal diffuse lung shadows on chest X-ray, in addition to clinical features suggestive of rheumatic disorders, i.e., arthralgia, Raynaud’s phenomenon, and skin rashes. Some patients may have presentations dominated by pulmonary manifestations over those of autoimmune disease. Thus, it is crucial for physicians to carefully evaluate the evidence of underlying CTDs in all patients who present with ILD.
ILD, especially IP, is one of the most common and clinically important complications of the various CTDs and the CTD-related disorders of which the most often implicated disorders are SSc, RA, PM/DM, Sjögren’s syndrome (SS), mixed connective tissue disease (MCTD), and SLE, according to prevalence [12, 13]. The frequency of ILD in CTDs is presented in Table 3 [12]. Essentially, as every component of the lungs is a potential target for CTDs, there is a wide variety of pulmonary manifestations associated with the diseases [13].
Connective tissue disease | Frequency of ILD | Patterns |
---|---|---|
Systemic sclerosis | 45% (clinically significant) | NSIP 80–90%, UIP 10–20%, OP, DAD |
Rheumatoid arthritis | 5–58% | UIP 50–60%, NSIP 30–60%, OP, LIP, DAD, DIP |
Polymyositis/dermatomyositis | 30–70% | NSIP, OP, UIP, DAD |
Sjögren’s syndrome | Up to 25% | NSIP, OP, UIP, LIP |
Systemic lupus erythematosus | 2–8% | NSIP, OP, UIP, DAD |
Mixed connective tissue disease | 20–60% | NSIP, OP, UIP, DAD |
Though the prevalence of ILD in CTDs varies based on patient selection and methods used for detection, the percentage appears to be higher than previously regarded. ILD may precede the extrapulmonary manifestations of CTD as a forme fruste of systemic disease, in some patients by years, while the rheumatic symptoms predate ILD in others [14–16]. Sometimes, it makes the distinction between idiopathic pulmonary fibrosis (IPF) and CTD-related ILD difficult [11, 16]. Despite similarities in clinical and pathologic presentation, the prognosis and treatment of CTD-associated ILD can differ greatly from that of other forms of ILD such as IPF [13, 16, 17]. Therefore, early detection of pulmonary involvement and early accurate diagnosis of CTDs are both important for initiating appropriate intervention. The multidisciplinary diagnostic team (MDD team), including a pulmonologist, a pathologist, and a rheumatologist, can contribute to it; a report indicates that 50% of patients referred with an initial concern for IPF had their diagnosis changed to a CTD-ILD after combined evaluation by the specialists [12].
The evaluation of ILD in patients with CTD is complex due to the heterogeneity of CTDs, the varied types and severity of ILD, and also the fact that ILD may be identified at any point in time in these patients. Fischer, et al. emphasize the importance of cross-disciplinary collaboration and thorough evaluations, which are needed either when CTD patients develop ILD or when encountering ILD patients with possible occult CTD [18]. The detection of occult CTD in patients with “idiopathic” ILD requires careful attention to historical clues, subtle physical examination findings, and autoantibody profiles, as well as radiologic and histopathological features. Such evaluation can be optimized by a multidisciplinary approach in collaboration with specialists including radiologists, pathologists, and rheumatologists. The standard clinical approach for evaluating patients with ILD for CTDs is well summarized by Vij R and Strek ME in their review [5].
Since the spectrum of ILD associated with CTD is broad, careful evaluation for autoantibodies or other serologic tests in conjunction with clinical features of autoimmune disease is crucial [19, 20]. Because of the variable incidence and outcome of ILD in CTD, biomarkers including autoantibodies are critical for diagnosis, prognosis, patient subtyping, and predicting response to treatment. Major autoantibodies and serologic tests commonly available for the evaluation of CTD-ILDs include antinuclear antibody (ANA), anti-double-stranded DNA, anti-ribonucleoprotein (anti-RNP) antibody, anti-Smith (anti-Sm) antibody, anti-scleroderma-70 (Scl-70) antibody, anti-Ro (SS A), anti-La (SS B), anti-Jo-1 antibody, rheumatoid factor (RF), and anti-cyclic citrullinated peptide antibody (ACPA) [5].
Some of the established biomarkers include lung epithelium-specific proteins [20]. Evidence indicates that repetitive injuries to alveolar epithelial cells (AEC) and airway Club cells trigger an exaggerated wound healing response. During the process, while AEC type I cells undergo apoptosis, regenerated hyperplastic AEC type II cells produce a vast array of cytokines, growth factors, and release surfactant proteins and mucins [21]. Surfactant proteins (SP-A and SP-D) and KL-6 in the serum are useful biomarkers, which have been well established for various ILDs. SP-D and SP-A, secreted by AEC II and airway Club cells, are surfactant lipoproteins and phospholipids which stabilize alveolar surface tension, playing an important role in the lung host defense system [22]. SP-D serum levels are more sensitive than SP-A in detecting ILD as defined by CT but less specific [23]. KL-6 is a high-molecular-weight mucin-like glycoprotein, now classified as MUC1, which is highly expressed by AEC II and bronchiolar epithelial cells and increases following cellular injury and/or regeneration [24]. KL-6 has profibrotic and antiapoptotic effects on lung fibroblasts [25]. Serum KL-6 has been shown to be elevated not only in IIP but also in CTD-ILD, as well as hypersensitivity pneumonitis, drug-induced pneumonitis, etc. [24, 26].
There are a number of principal autoantibodies which have been validated for the clinical use.Antinuclear antibody (ANA) determined by an immunofluorescence assay is most versatile, presenting with several major patterns; mainly homogeneous (associated with ANAs against double strand (ds) DNA in SLE and histones), speckled/peripheral (less specific), and nuclear (most often associated with limited scleroderma). ANA titer higher than 1–160 is regarded as significant in most laboratories [27]. When using enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA) for ANAs, we can detect single autoantigens such as dsDNA, Smith antigen, scleroderma (Scl-70) (also termed topoisomerase-1), SSA/Ro, SSB/La, etc. [27]. Some of the recent, newly developed autoantibodies with distinct clinical and immunological characteristics will be explained later.
Besides classical, well-established CTDs, increasing attention has been paid to pulmonary involvement in undifferentiated CTD (UCTD) [15, 17, 28–30]. UCTD has been generally defined as a condition that presents with signs and symptoms suggestive of CTDs along with positive ANA but does not fulfill any rheumatology classification criteria for specific CTDs [30, 31]. Mosca et al. reported that 60% of patients with UCTD remain undifferentiated. When evolution to defined CTD occurs, it usually does within the first 5 years of disease. UCTD may develop into any of the CTDs, most often into SLE [29]. There are a large number of patients, in whom the IP appears to be the lone part for the clinically predominant manifestation of an occult CTD with subtle clinical features that suggest an autoimmune process but not meet established criteria for CTD, raising a controversy over the strategies for identification and classification of these patients. Well-organized prospective studies have been needed to better understand this entity of the lung disease and distinguish it from the ILD with well-defined CTD or IIP. Proposed terminology to classify such patients includes “undifferentiated CTD” [31], “lung-dominant CTD” [15], and “autoimmune-featured ILD” [32]. Recently, the “ATS/ERS Task Force on Undifferentiated Forms of CTD-associated ILD” created consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity and proposed the term “interstitial pneumonia with autoimmune features” (IPAF). The classification criteria require evidence of IP and are organized around three central domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic, or pulmonary physiologic features [33]. Currently, it is not yet clear whether IPAF is a distinct phenotype of ILD or simply a part of IIP. Adopting IPAF classification may provide platform for the future study of a more uniform cohort, and prospective survey will be needed in determining efficacy of therapy and outcomes for the patients [34].
The underlying pathology in CTD-associated ILD can be dominated by inflammation or fibrosis or by a combination of both with distinct radiologic and histopathologic patterns [12]. Classification of histological and radiological patterns developed for IIPs is applied to CTD-ILD [1, 5, 11]. The radiological and corresponding histological patterns defining each entity of CTD-associated IP are summarized in Table 2 [11]. Although there is substantial histological overlap among the pulmonary manifestations of different CTDs and with other etiologies, certain histologic patterns may favor one CTD over another, and occasionally distinctive histologic clues may be present [35, 36]. It is possible in many cases to confirm CTD-ILD and guide patient management using histologic features. Pulmonary histopathology is thus helpful, and surgical lung biopsy remains the gold standard for evaluation of CTD-associated ILD [35]. ILD can present acutely or chronically, with acute presentations being more common in SLE and PM/DM. Histological patterns of CTD-associated IP include, most frequently, nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), diffuse alveolar damage (DAD), and lymphocytic interstitial pneumonia (LIP). By contrast, desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis-associated interstitial pneumonia (RB-ILD) are uncommon forms of IP in CTD. Both, typically affecting cigarette smokers, share overlapping clinicopathological features and have a relatively better prognosis than UIP.
In the history of classification, the recognition that the cases of ILD exist from which lung biopsy samples do not fit into any well-defined histologic patterns of idiopathic IP led to proposals of the terms “unclassified interstitial pneumonia” by Kitaichi in 1990 [37] and “nonspecific interstitial pneumonia/fibrosis (NSIP)” by Katzenstein and Fiorelli in 1994 [38]. This novel concept has helped to identify a group of ILDs with a more favorable prognosis and which needs to be distinguished from IPF/UIP, while also having different characteristics from DIP, AIP, and COP [1]. Katzenstein, in her large study of 64 such cases, utilized the descriptive term “nonspecific interstitial pneumonia/fibrosis (NSIP),” which was characterized by varying proportions of interstitial inflammation and fibrosis that appeared to be occurring over a single time span (i.e., a temporally uniform process). NSIP may have varying etiologies, including underlying CTD as well as organic dust or other exposures [38]. Subsequent intensive studies in collaboration with pathologists and radiologists have endorsed its differentiation from other types of IP, gaining the term NSIP, a broad acceptance [39, 40]. NSIP pattern of lung injury, itself further subdivided into cellular and fibrotic NSIP, is the most common pattern of IP in all CTDs except for RA, in which UIP pattern pathology may be more common [41, 42]. NSIP lung injury is characterized by diffuse, although often variable, alveolar septal thickening due to collagen deposition. The amount of associated interstitial inflammation varies, but in most cases, it consists of mild patchy lymphoplasmacytic infiltrate. Although NSIP is not a pattern specific to CTD-IP, there are several histologic clues which support CTD, and when found, make the diagnosis of CTD-IP more likely [35].
Involvement of multiple lung components: concurrent involvement of alveolar septal interstitium, airways, vessels, and pleura is an important clue to the diagnosis of CTD-IP and can be helpful in differentiation of it from IPF.
Interstitial fibrosis with overlapping NSIP and UIP: a histologic overlap of UIP and NSIP patterns is frequently shown in CTD, although similar findings may be seen in some variants of chronic hypersensitivity pneumonia, etc.
Lymphoid aggregates: formation of prominent lymphoid aggregates, often with germinal centers, is a characteristic feature of CTD-IP, classically seen in RA and Sjögren’s syndrome.
UIP is the prototype of histopathology which characterizes IPF, a chronic form of idiopathic interstitial lung disease [1, 2]. UIP pattern is often encountered in CTD-IP, with more prevalence in advanced cases. This pattern is classically identified by its patchy nature (spatial heterogeneity) and chronic active appearance (temporal heterogeneity). Fibrosis is accentuated in the subpleural regions with microscopic honeycombing observed as irregular airspaces surrounded by dense fibrosis. Fibroblast foci (regions of new fibrosis) are found at the interface between central and peripheral regions [35]. While primary UIP pattern is found in 13–56% of RA-ILD cases, some studies have reported that the most frequent histologic pattern of ILD among RA patients is NSIP, followed closely by UIP, accounting for 30–67% and 13–57% of RA-ILD, respectively [36]. Studies of PM/DM-ILD identified an UIP pattern in 5–33% of cases. In SSc-ILD, UIP pattern was found in 15% in one study and 26% in another. UIP pattern has also been reported in 17% of Sjögren’s syndrome cases in a study. Whereas idiopathic pulmonary fibrosis (IPF) is a progressively deteriorating ILD, in which the characteristic histological pattern of IPF is UIP; interestingly, a UIP pattern is associated with a significantly better survival in CTD compared to the IPF [43]. Histologically, CTD-associated UIP biopsies had fewer fibroblastic foci, smaller honeycombing spaces, higher numbers of germinal centers, and higher inflammation scores than IPF/UIP biopsies [44].
Since 1935, when Louis Hamman and Arnold Rich described four patients with acute respiratory failure of unknown etiology, the existence of cases which manifest acute respiratory failure with bilateral lung infiltrates has been recognized [45]. All four patients died and were revealed at autopsy to have a distinctive pathology that in modern times is recognized as the organizing stage of diffuse alveolar damage (DAD). This acute idiopathic respiratory condition was subsequently given the eponym Hamman-Rich syndrome. Although the histology of DAD was described even earlier, the term of “diffuse alveolar damage” (DAD) was presented by Katzenstein, et al. in their comprehensive review with their own data [46]. They concluded that endothelial and alveolar cell injury leads to fluid and cellular exudation, with hyaline membranes and edema being well-known features.
The term “acute interstitial pneumonia” (AIP) was introduced in 1986 by Katzenstein et al. for cases identical to the Hamman-Rich syndrome to lay emphasis on the fact that the condition is an acute form of idiopathic interstitial lung disease, clinically and histologically distinct from chronic forms, the prototype of which is IPF [47]. The prognosis of AIP is dismal and the mortality high. Today, AIP is defined by the following key elements: acute onset of respiratory symptoms typically resulting in acute respiratory failure; bilateral lung infiltrates on radiographs; the absence of identifiable etiology; and histological documentation of DAD [1, 47, 48]. Whereas the term AIP is applied when DAD is of unknown etiology, similar injury due to a known cause is generally referred to as DAD (stating the cause or the underlying disease).
DAD is thus a histologic pattern of injury usually associated with a life-threatening acute or subacute presentation which often correlates with the clinical entity of acute respiratory distress syndrome (ARDS) [49]. In earliest phase, the histology of DAD comprises alveolar septal edema and fibrin deposition in airspace. Over hours to days, these changes are accompanied by fibroplasia in alveolar septa, accumulation of alveolar macrophages (including foam cells), and formation of hyaline membranes [50]. Organizing thrombi are often found in small to medium-sized arteries. Within days to weeks after injury, airspace plugs of organizing pneumonia and type II pneumocytes hyperplasia on alveolar surfaces become prominent, representing a histologic pattern described as “organizing DAD.”
Besides AIP, infection is the most important etiology to exclude in patients in whom a diagnosis of AIP is clinically considered. Infectious etiology includes fungi, pneumocystis organisms, and viruses such as cytomegalovirus (CMV), etc. Despite prominent neutrophilia observed in bronchoalveolar lavage (BAL) fluid samples, there is usually a paucity of inflammatory cells on histologic sections in case of AIP. If prominent acute inflammation is seen, particularly in the airspaces, it raises suspicion of infection. Other clues to specific etiologies include viral cytopathic changes observed in some viral pneumonias (e.g., cytomegalovirus, respiratory syncytial virus, adenovirus); food or other foreign material (with or without giant cell reaction) suggesting aspiration; and prominent eosinophilia suggesting a primary eosinophilic disorder such as eosinophilic granulomatosis with polyangiitis (EGPA/Churg–Strauss syndrome) or acute eosinophilic pneumonia [35].
CTDs are another major group of diseases that may manifest pathologically as DAD. To identify CTD as an etiology of DAD in patients, exclusion of other possible cause must be established. Of note, DAD usually occurs in patients with established CTD-ILD but also can occasionally be the presenting manifestation of the disease [51]. In CTD patients who initially present with DAD, rheumatologic manifestations and serological tests should help to establish the correct diagnosis. In patients with CTD on immunosuppressive therapy, infectious etiology and drug toxicity should be considered as a potential cause of DAD. In SLE, cases of diffuse alveolar hemorrhage commonly show histological features of DAD [52]. In PM/DM, an older case series found DAD pattern in 4 of 15 cases (27%); a more recent series identified DAD in 2 of 70 cases (3%), possibly reflecting improvements in diagnosis and treatment of this disease [53, 54]. A study suggests that DAD is more common in DM-ILD than in PM-ILD [55]. In RA, one study reported primary DAD pattern found in 2 of 33 cases (6%) [56]. In a more recent study of CTD-associated DAD, RA accounted for five of nine cases; in four cases, DAD occurred in patients with established, pre-existing RA-ILD, whereas one manifested as a de novo presentation [51].
While OP is characterized by fibrosis and chronic inflammation like IP, it differs in that the reaction affects predominantly the airspaces rather than the interstitium; this disorder is not an interstitial process [57]. However, many include OP in the classification of IP [40]. OP is histologically characterized by consolidation of airspaces by rounded branching polypoid plugs of granulation tissue [35]. This airspace organization is usually found in the alveoli as well as terminal airways. Pure involvement of airways is rare, and thus, it should raise suspicion of a primary small airway disease. Alveolar macrophages with foamy cytoplasm are often found; however, this nonspecific finding may also be observed in cases of aspiration or drug toxicity. Usually, there are not abundant neutrophils in the histology of OP. If prominent inflammation, particularly involving the airspaces, is found, it should raise suspicion of infection as a cause. Also, when eosinophils are prominent in the airspace, suspicion of a primary eosinophilic disorder, e.g., EGPA/Churg-Strauss syndrome, eosinophilic pneumonia, etc., or a drug adverse reaction must be raised. Overall, a predominant OP pattern, if encountered, accounts for a broad range of differential diagnosis to be considered, which include CTD, infectious pneumonia (particularly viral or atypical bacterial), aspiration, and drug toxicity. Thus, after all diagnostic exclusion is made, cryptogenic organizing pneumonia (COP) is determined as the diagnosis.
In many cases of CTD, the associated ILD may demonstrate focal lesions of OP pattern superimposed on a background of the other patterns of IP, frequently seen in NSIP. Therefore, true OP is less common in CTD-ILD. Among the RA-ILD, one study reported a primary OP pattern in 2 of 18 cases of RA-ILD (11%), and another stated 6 of 40 cases (15%) [42, 56]. Of note, OP can occasionally be the inaugural manifestation of RA [58]. In PM/DM-ILD, OP is common; OP as the primary pattern was present in 6 of 15 cases (40%) in one series, 5 of 13 (38%) in another [53, 59]. In a study of cases with Sjögren’s syndrome reported, OP was found in 4 of 18 biopsies (22%) in the series [51]. By contrast, OP is a very rare manifestation in SSc; detected only in 1 of 80 cases in a large series [60].
The term “lymphocytic interstitial pneumonia” (LIP) refers to a pattern of IP in cases with diffuse and marked thickening of alveolar septal interstitium predominantly by dense lymphocytic infiltrate [61]. The infiltrate is polyclonal and may be admixed with variable numbers of plasma cells and macrophages. Germinal centers are frequently present. Histologically, LIP overlaps with follicular bronchiolitis and nodular lymphoid hyperplasia. When present, LIP pattern may raise concern for a possible lymphoproliferative process, which should be ruled out using appropriate immunohistochemical studies and flow cytometric analyses [35]. It should be noted that LIP has been associated with some viral infections, particularly human immunodeficiency virus. Classically, LIP was well-recognized in Sjögren’s-associated ILD, where it was initially reported in at least 25% of cases based on a series of 12 biopsies [62]. A more recent study identified LIP primary pattern in 3 of 18 cases of Sjögren’s-ILD (17%) [51].
SSc is recognized as the CTD with the highest prevalence of ILD, ranging from 40 to 80%, depending on the modalities used for ascertainment [63]. The frequency of ILD varies according to patient selection, subsets of skin disease extent and ethnicity. In a large autopsy study, ILD was the most common pulmonary lesion in SSc, being found in >70% of the cases, and arteriolar thickening, described as medial hypertrophy or concentric intimal proliferation, was the most specific lesion in the lungs suggestive of pulmonary hypertension, being noted in 29% of the patients [64]. SSc, classically “scleroderma,” is defined by the presence of major criteria; i.e., skin thickening proximal to metacarpo-phalangeal joints and minor criteria; i.e., sclerodactyly, esophageal involvement, and lung fibrosis [65]. It is subdivided into a limited cutaneous form, including CREST (Calcinosis, Raynaud’s syndrome, Esophageal dysmotility, Sclerodactyly, Telangiectasia) syndrome and a diffuse cutaneous form (diffuse SSc has skin sclerosis proximal to elbows and knees), with varying degrees of skin, esophageal, lung, cardiac, and vascular involvement. Both forms can be progressive in nature.
As mentioned above, pulmonary manifestations in SSc include ILD and vascular disorder manifesting as pulmonary arterial hypertension (PAH). Today, both pulmonary complications are the leading cause of morbidity and mortality in patients with SSc. In line with SSc as the vasculature disorder, ranging from Raynaud’ s phenomenon to PAH and renal crisis, nailfold capillary microscopy is now a well-established measure to evaluate capillary damage or abnormality [66]. The capillary changes observed in digits can be a predictor of severe vascular complications, being helpful in recognizing early disease [67].
In the context of autoantibodies, anti-nuclear antibodies (ANA) are found in the majority of SSc patients although not in every case. In 2013, the novel classification criteria of American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) collaborative initiative for SSc incorporated three major autoantibodies [68]. These antibodies with high specificity for SSc are against topoisomerase (ATA or anti Scl-70), anticentromere antibodies (ACA), and anti-RNA polymerase III (ARA). They are closely related to distinct disease patterns; anti-topoisomerase antibodies are strongly associated with ILD, whereas anticentromere antibodies are highly predictive of the absence of significant lung fibrosis but associated with development of pulmonary hypertension [69]. Anticentromere antibodies, which are frequently found among Caucasians (20–35%), are strongly indicative of a limited form disease referred as CREST syndrome [69]. The other major autoantibody, anti-RNA polymerase III, is linked to diffuse skin disease and renal crisis, with less significant lung fibrosis. This antibody has another aspect that may herald paraneoplastic SSc [70]. While almost all patients with anti-topoisomerase antibodies have some extent of ILD, more than half of the SSc patients with ILD are negative for this antibody.
The most common pattern of ILD in SSc is fibrotic NSIP which manifests as dense, paucicellular interstitial fibrosis that maintains the underlying architecture [60, 71, 72]. As the lung disease progresses, the areas of fibrosis may become confluent and appear as honeycomb. SSc patients may also present with typical UIP pattern with temporal and special heterogeneity, in contrast to the diffuse and uniform fibrosis of NSIP. In most SSc patients, ILD remains stable without treatment despite having some degree of lung fibrosis. However, some proportions of the SSc patients develop significant and progressive ILD. In SSc-associated ILD, placebo-controlled randomized trials, named the Scleroderma Lung Study (SLS) and the fibrosing alveolitis scleroderma trial (FAST), have been performed, suggesting certain effectiveness of immunosuppressive therapy in preventing further decline in patients with progressive ILD to be mentioned later [73, 74].
RA is the most common CTD, occurring in 1–2% of the population, more frequently in women. Although RA is primarily characterized by synovial inflammation which leads an erosive inflammatory polyarthropathy, predominantly affecting the distal joints, extra-articular manifestations are seen in approximately half of patients with RA. Extra-articular manifestations include subcutaneous nodules, skin ulceration, scleritis/episcleritis, pericarditis, splenomegaly, and a variety of pleuro-pulmonary abnormalities.
Lung disease accounts for 10–20% of mortality in RA, second only to cardiac disease [75–77]. Airway, pleural, vascular, and parenchymal involvement can occur in RA patients, as well as pulmonary disorders indirectly associated with RA such as opportunistic infections and drug-induced lung disease. All pleuro-pulmonary manifestations in RA are more common in males; ILD affects men twice as commonly as women. The prevalence of ILD ranges widely from 5 to 58% in various reports [78–80]. It is difficult to confirm the exact prevalence because it depends on modalities of ascertainment and patient selection such as autopsy, hospital, and community-based studies. In a study of 36 patients with new onset RA, abnormalities consistent with ILD were found in 58% of patients; physiology 22%, chest X ray 6%, HRCT 33%, BAL 52%, and 99mTc-DTPA radionuclide scan 15% [81]. Smoking is a significant risk factor for ILD; an odds ratio of 3.8 for ILD was observed in RA patients with a smoking history >25 pack years [82].
In the context of histological patterns, the predominant ILD histology in RA patients is NSIP (cellular or, more commonly, fibrotic NSIP), followed closely by UIP, accounting for 30–67% and 13–57% of RA-associated ILD, respectively [42, 44, 59, 83–85]. Some studies have noted greater incidence of UIP histology in RA-ILD found in up to 56% of patients in a series [42]. These NSIP and UIP patterns are followed by organizing pneumonia (OP). There is evidence suggesting that a UIP pattern may be associated with a worse survival than fibrotic NSIP in cases of RA, in contrast with the other CTDs. A pattern of DAD/acute interstitial pneumonia (AIP) is infrequent but may occur as fulminant ILD manifestation of RA, which can develop in a previously normal lung or as the presenting pattern of a previously undiagnosed ILD. The characteristic CT pattern of DAD includes widespread ground glass with/without areas of dependent consolidation, although a similar pattern could represent opportunistic or viral infection and acute heart failure.
Idiopathic inflammatory myopathy (IIM), a group of systemic autoimmune disorders that affect skeletal muscles and other organs, comprises three major categories: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). PM and DM are sometimes recognized together as they share similar clinical signs and symptoms with exception of cutaneous manifestations such as “heliotrope rash” on the upper eyelids, “mechanic’s hands” on the fingers, and “Gottron papules” on the dorsal surface of the hands seen in DM. Pathologically, however, these are distinct entities; PM is T cell-mediated diseases, where CD8-positive cytotoxic T cells invade muscle fibers expressing MHC class I antigens, whereas DM is characterized by a complement-mediated microangiopathy [86–88].
The diagnosis of PM/DM is made on the basis of clinical features and examinations, which include symmetrical proximal muscle weakness, elevated serum muscle enzymes, characteristic electromyographic alterations, muscle biopsy histopathology consistent with myositis, and for DM, typical cutaneous manifestations mentioned above and less-specific skin rashes. Moreover, muscle magnetic resonance imaging (MRI) and ultrasound (US) have been also introduced in the diagnostic work up of patients with inflammatory myopathies. Classification criteria for PM/DM date back to initial publications by Medsger et al. [89]. Since, in 1975, Bohan and Peter classified myositis, their criteria have been widely used [90, 91]. However, it demonstrated poor specificity and cannot distinguish PM from IBM or some forms of dystrophies for instance. Thus, several diagnostic criteria for inflammatory myopathies have been proposed with little acceptance, including recent muscle-biopsy-based diagnostic criteria [92]. Further prospective studies are required to develop improved and universal classification criteria.
Several neuromuscular diseases which may mimic PM/DM and should be considered in the differential diagnosis include drug or toxic myopathies (alcohol, colchicine, statins, etc.), endocrine myopathies (hyper-hypothyroidism), metabolic myopathies, mitochondrial myopathies, muscular dystrophies, infectious myositis, neuropathies, paraneoplastic syndromes, other connective tissue disorders, amyloidosis, and sarcoidosis [93]. Muscular dystrophies, where an increase of creatine kinase (CK), electrodiagnostic, and bioptic abnormalities similar to PM/DM may be present, can be distinguished from DM/PM by the positive family history, the relatively early insidious onset, and slow progression. Iatrogenic myopathy is secondary to corticosteroids use, where CK is normal and the histological examination shows atrophic changes of muscle fibers. Other diseases to consider in the differential diagnosis are endocrine or dysionemia-induced myopathies. Rheumatic polymyalgia (polymyalgia rheumatica) is characterized by normal CK and histological absence of inflammatory abnormalities. Infectious myositis especially viral and parasitic myositis are characterized by a diffuse muscular involvement and a subacute or chronic course. Bacterial myositis is localized and acute. Among other rare inflammatory myopathies, nodular focal myositis is considered as a variant of PM/DM and may present at onset (As localized, a differential diagnosis with muscular cancers and/or thrombophlebitis must be considered). Eosinophilic myositis, characterized by muscle eosinophil infiltrate, may be part of a hypereosinophilic syndrome (pneumonia, endocardial and myocardial fibrosis, and peripheral neuropathy, etc.) or be associated with eosinophilic fasciitis. Granulomatous myositis can be isolated or in the context of granulomatous syndromes, such as sarcoidosis or Crohn’s disease; the main histological finding is the presence of granulomatous lesions which may contain epithelioid cells, histiocyte, and Langerhans giant cells. In the differential diagnoses of IBM, polyneuropathy and amyotrophic lateral sclerosis have also to be considered [93, 94].
Concerning extra-muscular involvement, respiratory disease is a major cause of morbidity and mortality in PM/DM [53, 95–100]. PM/DM-associated pulmonary disorders may manifest as ILD and as a consequence of respiratory muscle weakness leading to hypoventilation or aspiration pneumonia. ILD is the most common extra-muscular complication in PM/DM and have been recognized in 30–70% of the patients [100–102]. The reported prevalence varies depending on the modalities or tests for detection and patient selections. Since Tazelaar et al. reported a histopathological study of lung biopsy specimens in patients with PM/DM in terms of treatment responses and survivals, histopathology fairly serves relevant clinical decisions [53]. As for the prevalence of the different histopathologic patterns, NSIP is by far the most frequent finding, followed by DAD, UIP, and OP [54, 103–107]. Our study with HRCT scans of 14 cases of histologically proven NSIP associated with PM/DM showed that the predominant features were of reticular and/or ground-glass opacities with or without consolidation. Reticular and ground-glass opacities predominated in the lower zone of each lung, and consolidation predominated at the lung periphery [108].
In the context of subtypes of PM/DM, the following concepts of amyopathic dermatomyositis and anti-synthetase syndrome warrant particular attentions.
Clinically amyopathic dermatomyositis (CADM), which is characterized by the cutaneous findings of DM with no muscle involvement or only minimal weakness, affects approximately 20% of patients with DM [109, 110]. Patients with CADM have a greater risk of developing ILD, especially prone to rapidly progressive lung disease corresponding to DAD [111, 112]. Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (also referred to as anti-CADM-140 antibodies) were identified in the serum from patients with CADM by firstly immunoprecipitation assays [113]. The presence of anti-MDA5 antibodies is strongly associated with DM, especially with CADM, and rapidly progressive ILD, which are thus associated with particularly poor clinical outcomes.
A subset of patients may manifest a clinical syndrome known as “anti-synthetase syndrome (ASS),” which is characterized by the presence of one of the anti-aminoacyl-t-RNA synthetase (ARS) antibodies such as anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, and anti-KS, together with stigmata of PM/DM including myositis, ILD, polyarthritis, fever, Raynaud’s phenomenon, and mechanic’s hand [114, 115]. Anti-Jo-1, the first anti-ARS antibody, is the best understood of the anti-synthetase antibodies, with a strong correlation with ILD in patients with PM/DM; the incidence of ILD approaches 90% [116, 117].
Circulating autoantibodies directed against nuclear or cellular components are frequently detected in patients with PM or DM. These antibodies are categorized into two groups; one is specific to PM/DM, whereas the other is found in overlap syndrome with myositis. Targoff et al. designated these two categories of autoantibodies as “myositis-specific antibodies; MSAs” and “myositis-associated antibodies; MAAs,” respectively [114]. Classical autoantibodies such as anti-aminoacyl transfer RNA synthetases (ARS) antibodies, anti-signal recognition particle (SRP) antibodies [118, 119], and Mi-2 antibodies are classified as MSAs, where especially anti-Mi-2 antibodies are DM specific [120]. Later, the new DM specific antibodies have been disclosed. These include the antibodies directed against melanoma differentiation–associated gene5 (MDA5) (anti-CADM-140 antibody, mentioned above) [113, 121, 122], transcriptional intermediary factor-1-gamma (anti-p155 antibody) [123, 124], NXP-2 (anti-NMP-2 antibody) [125, 126], and small ubiquitin-like modifier activating enzyme (anti-SAE antibody) [127]. Usually, MSAs are distinct, and their presence is mutually exclusive.
Because of their strong associations with a pattern of clinical features, such as myopathy, skin lesions, and ILD, these novel autoantibodies are useful biomarkers for classifying disease subgroups, predicting future organ involvement, and forecasting the prognosis of patients with PM/DM [114, 128–131]. The autoantibodies are detectable in PM/DM; both MSA and MAA are listed and summarized in Table 4 [102]. The pathogenetic mechanisms of expression of such autoantibodies are still awaited to be illuminated.
Autoantibodies | Antibody target | Frequency in polymyositis/ADM/JDM % | Frequency of ILD in adult /juvenile myositis % | Clinical spectrum | |
---|---|---|---|---|---|
In adulthood | In childhood | ||||
Myositis- specific autoantibodies (MSA) | |||||
Anti-t-RNA synthetase | 29/20/5 | ||||
Anti-Jo1 (PL1) | Histidyl-ARS | 21/11/<3 | 66/63 | Arthralgia, fever, RP, mechanic’s hand, puffy finger | Arthralgia, fever, RP, mechanic’s hand, sclerodactyly |
Anti- PL7 | Threonyl-ARS | 5/2/<1 | 84/63 | ||
Anti- PL12 | Alanyl-ARS | 2/3/<1 | |||
Anti-KS | Asparaginyl-ARS | <1 | |||
Anti-OJ | Isoleucyl-ARS | <1 | |||
Anti-EJ | Glycyl-ARS | <1 | |||
Anti-SC | Lysyl-ARS | <1 | |||
Anti-JS | Glutaminyl-ARS | <1 | |||
Anti-YRS(Ha) | Tyrosyl-ARS | <1 | <1 | ||
Anti-Zo | Phenylalanyl-ARS | <1 | |||
Dermatomyositis Specific autoantibodies | |||||
Anti-Mi2 | Nucleosome remodeling deacetylase complex | 1/9/4–10 | 4/0 | Classical DM without extramuscular involvement | Mild or moderate JDM |
Anti-NXP2(MJ,p140) | Nuclear matrix protein 2 | 10/0–3/12–25 | 0/25 | DM without extramuscular involvement, calcinosis | Mild or moderate JDM |
Anti-MDA5(CADM-140) | Melanoma differentiation-associated gene encoding RNA helicase | <1/14–46/7 | Europe:60; Asia:90/Europe:19; Asia:53 | Amyopathic DM, severe cutaneous ulcers, rapidly progressive ILD | Severe cutaneous ulcers, RP-ILP, mediastinal emphysema |
Anti-TIF1γ(p1555/140) | Transcriptional intermediary factor 1γ | <1/10–30/14–29 | <10/3 | Cancer associated DM in 78% of cases | Mild or moderate JDM |
Other MSA | |||||
Anti-SRP | Signal recognition particle | 5/1/<3 | 15/0 | Necrotising myopathy | Severe JPM |
Anti-HMGR(200-100) | 3-hydroxy-3-methylglu taryl-coenzyme A reductase | 10/<1/unknown | Unknown | Necrotising myopathy | Unknown |
Anti-SAE | Small ubiquitin-like modifier activating enzymes | <1/5–10/1–9 | DM | Unknown | |
Myositis associated autoantibodies | |||||
Anti-RO/SSA | RNP complexes with small cytoplasmic RNAs(hy-RNA) | 12/13/0 | |||
Anti-U1RNP | 70 KDa,A and C polypeptides of U1 snRNP | 5/6/6 | 7 | DM, fever, RP, sclerodactyly | |
Anti-PM/Scl(75 and 100 Kda) | PM/Scl complex encompassing C1D,PM-SCl-100 and PM-SCl-75 proteins of the human exosome | 6/9/4 | 38 | Fever, RP, sclerodactyly | |
Anti-Ku | 80 and 70 KDa DNA binding dimeric protein | 2/1/0 | 27 | Fever, RP, sclerodactyly |
Autoantibodies in polymyositis/dermatomyositis.
ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; ILD: interstitial lung disease; SRP: signal recognition particle; ARS: aminoacyl-t-RNA synthetase; RP: Raynaud’s phenomenon; DM: dermatomyositis specific rash; RP-ILP: rapidly progressive ILD; JPM: juvenile poly myositis
Adapted from Lega et al. [120].
Numbers of studies on the pathogenesis of IP have been performed in SSc as well as in mouse models of IP, providing evidence for plausible mechanisms that may lead to pulmonary fibrosis in CTD. This is natural because, among the whole CTDs, SSc has the highest prevalence of IP, and currently, the lung disease consists the major cause of death in patients with SSc, being shifted away from mortality due to renal crisis which was more common in the past. The high morbidity and mortality due to IP in SSc have been eliciting not only multidisciplinary clinical studies but also basic researches. Many lines of evidence acquired from the studies on SSc, and relevant researches on fibrosis have been implying the following potential scenario of classic mechanisms in the pathogenesis of CTD-IP [12, 132, 133].
The key mechanisms in CTD-IP involve an interplay between various cell types and humoral factors; the pathogenesis is initiated by microvascular injury, leading to endothelial cell damage and alveolar epithelial injury [12, 132, 133]. This is followed by activation of the coagulation cascade, release of various cytokines, e.g., IL-1, IL-4, IL-6, IL-13, chemokines, and lysophosphatidic acid (LPA), and growth factors including transforming growth factor beta (TGF-β), connective tissue growth factor (CTGF), and insulin-like growth factor (IGF-1), which leads to activation of fibroblasts, resulting in the development of fibrosis [12, 132, 134]. Many epithelial-derived factors influence the behavior of fibroblasts, with soluble mediators known to exhibit profibrotic activities [134]. The pivotal mediator of fibrosis is the multifunctional cytokine, TGF-β, which, along with platelet-derived growth factor, endothelin-1 (ET-1), plays a major role in the pathogenesis of SSc. There is evidence that epithelial-to-mesenchymal transdifferentiation (EMT) occurs in lung fibrosis, and this process is mediated by TGF-β and potentially ET-1 [135, 136]. TGF-β responses are mediated by canonical Smad signaling [137]. Binding of TGF-β to its receptor elicits signaling through phosphorylation and nuclear translocation of cytoplasmic Smad protein, triggering transcription of genes such as type I collagen, fibronectin, α-smooth muscle actin, and CTGF, which promote fibrogenesis [138]. ET-1 is a potent vasoconstrictor produced by endothelial cells, epithelial cells, and mesenchymal cells. ET-1 binds to ET-1A and ET-1B receptors, recruits fibroblasts, stimulates extracellular matrix production, and also stimulates TGF-β production in lung fibroblasts [139]. Elevated levels of ET-1 have been found in the blood vessels, lung, kidneys, and skin of SSc patients [140]. LPA is produced by activated platelets and fibroblasts. The LPA receptor is expressed in fibroblasts, endothelial cells, and epithelial cells. Both are involved in the development of lung fibrosis in mouse model of IPF, suggesting LPA mediates fibroblast recruitment [141]. IGFs have been implicated in pulmonary fibrosis because increased levels of IGF-1 are detected in the serum as well as in the BAL of SSc patients [142]. CTGF, also known as CCN2, which plays a pivotal role in the stimulation of extracellular matrix production and myofibroblast differentiation, is involved in angiogenesis and forming the connective tissue [143]. The levels are elevated in the skin and lungs from SSc patients as well as in the sera [144].
The earliest events of the parenchymal lung involvement in CTD include inflammation and associated alveolar epithelial injury which occurs due to undetermined causes or can be caused by some environmental pathogens. The alveolar epithelial damage and inflammation let resident fibroblasts of pulmonary interstitium to locate to the alveolar wall, and the fibroblasts become activated through a variety of mediators such as TGF-β [145, 146]. The activation of resident fibroblasts was shown to be induced by the recruitment of active TGF-β from the lung tissue [147]. The resident lung fibroblasts play a pivotal role in lung fibrosis, and they are considered to be a more primitive or less differentiated lineage of fibroblasts that are prepared for repair at injury response [148]. The recruitment of activated fibroblasts and myofibroblasts that produce large amount of extracellular matrix proteins occurs in the process. These population of cells are not only derived from resident interstitial fibroblasts but also come from circulating progenitor cells which include mesenchymal stem cells recruited from the bone marrow and cells of a monocyte lineage that localize to the lung [149]. Myofibroblasts persist as critical profibrotic cells in affected lung tissue. It is conceivable that minor injury and subsequent disease process lead to the development of a lung microenvironment prone to fibrosis. That series of events results in an accumulation of constituents of the extracellular matrix (ECM), which remodels normal tissue architecture, which in turn culminates in pulmonary organ failure. Essentially, the lung is primed to develop fibrosis in response to injury, and it is likely that the intrinsic response is more severe in CTDs than normal individuals. Thus, in SSc, such genetic or intrinsic differences can be reflected to the serological phenotypes such as the expression of autoantibodies. Patients with SSc having anti-topoisomerase antibodies are liable to develop significant lung fibrosis, while those with anti-RNA polymerase III antibodies are less [150].
The immune system is also implicated in the pathology of SSc. Several lines of evidence suggest that a specific population of activated T cells exhibiting type 2 helper T (Th2) phenotype potentially mediates tissue fibrosis, secreting IL-4 and IL-13 both of which activate fibroblasts and collagen production by inducing TGF-β [151]. In SSc, T cells with memory phenotype were found in lung biopsy specimens from patients with lung involvement [152]. In some studies reported, increased numbers of lung memory CD8 T cells are associated with more severe pulmonary fibrosis [153–155]. Luzina et al. have shown an increase in CD8 T cells in the lungs of SSc patients by using T cells isolated from BAL fluid and demonstrated that a subset of patients at higher risk of progressive lung disease had activated, long-lived CD8 T cells which could promote fibrosis through production of profibrotic factors such as IL-4 and oncostatin M, as well as activation of TGF-β [156]. Regulatory T cells (Tregs) which maintain self tolerance can be impaired in their ability to suppress CD 4 effector T cells [157]. Currently, the precise knowledge of the role of effector cells in innate and adaptive immune system in SSc-associated IP is rather insufficient. More fundamental investigations in this aspect are needed to address to many queries as to the whole scenario of the development of IP in CTDs.
Besides, as concerns idiopathic pulmonary fibrosis (IPF), the latest evidence of immune mechanisms in IPF was reviewed in the recent literature, which includes involvement of both innate immunity and adaptive immunity at several levels of the processes toward development of fibrinogenesis in the human lung of IPF or in its model mice, as summarized in Table 5 [158]. Briefly, in adaptive immune system, the role of T cells seems complex and subset dependent; Th2 and Th17 cells were shown to promote pulmonary fibrosis, although Th1, Th22, and γδ-T cells have been found to attenuate fibrotic disease. Treg and Th9 subsets have been proposed to exert both anti- and profibrotic effects. In innate immunity, M2 macrophages and neutrophils have been suggested to enhance pulmonary fibrosis, whereas M1 macrophages were assigned a protective role, but contradictory findings have also been described [158].
Cells and mediators | Description |
---|---|
Immune cells T cells | Th1 cytokines (IFN-Y and IL-12) attenuate PF, Th2 cytokines (IL-4, IL-5 and IL-13) enhance PF, Th17 cells enhance PF, Tregs and Th9 (IL-9) have both pro- and antifibrotic roles in PF; Th22 (IL-22) and Yδ-T cells have an antifibrotic role in PF. |
Macrophages | M1 marcrophages induce myofibroblast apoptosis and digest ECM by activation of MMPs. M2 macrophages recruit and activate fibroblast through TGF-β1 and PDGF secretion. M2 macrophages further produce TIMPs and inhibit degradation of ECM. Both Macrophages phenotypes (M1/M2) can exert pro- and antifibrotic effects. |
Neutrophils | Neutrophils produce elastase, MMPs, and TIMPs. Neutrophil elastase activates TGF-β and recruits inflammatory cells to the lung, thereby promoting PF. |
Fibrocytes | Fibrocytes produce ECM, cross-linking enzymes, chemokines, growth factors, and MMPs, and promote PF. Fibrocytes secrete paracrine mediators, which activate resident fibroblasts to promote PF. Fibroblasts can differentiate into fibroblasts and myofibroblasts. |
Cytokines | |
IL-1β | Profibrotic effects of IL-1β, mediated through IL-1R/MyD88 signaling pathway. |
IL-13 | IL-13 differentiates human lung fibroblast to myofibroblast through a JNK-dependent pathway. |
IL-17 | IL-17 interacts/cooperates with TGF-β signaling to promote PF. |
TGF-β1 | TGF-β promote EMT through SMAD-2/3 signaling pathways. TGF-β1 induces PF through ERK, MAPK, PI3K/Akt, and Rho-like GTPase pathways. TGF-β1 differentiates fibroblasts into and increase ECM accumulation. |
PDGF | PDGF stimulates fibroblasts and increase ECM gene expression in fibroblasts. |
Chemokines | |
CCL2 | CCL2 increase fibrocyte recruitment and differentiation into fibroblasts, resulting in excessive collagen deposition. CCL2 activates M2 macrophage activation and promote PF. |
CCL17 | CCL17 promotes PF through the recruitment of CCR4^+ Th2 cells and alveolar macrophages. |
CCL18 | CCL18 increase collagen production in lung fibroblasts through ERK1/2, PKCα, and Sp1/Smad3 signaling pathways. |
CXCL 12 | CXCL 12 recruits fibrocytes and activates the Rac1/ERK and JNK signaling pathways to induce AP-1 activation and CTGF expression in fibroblasts |
Possible immune mechanisms for pulmonary fibrosis.
Definition of abbreviations: Ap-1, activator protein 1; CCL, CC chemokine; CTGF, connective tissue growth factor; CXCL, CXC chemokine ligand; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; ERK, extracellular signal-regulated kinase; IL-1R1, IL-1 receptor 1; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; MyD88, myeloid differentiation primary response gene 88; PDGF, platelet-derived growth factor; PF, pulmonary fibrosis; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; Rac 1, Ras-related C3 botulinum toxin substrate 1; SMAD, SMA/MAD homology; Sp1, specificity protein 1; TGF, transforming growth factor; TIMP, tissue inhibitors of metalloproteinase; Tregs regulatory T cells.
Adapted from Kolahian et al. [158].
After all, a variety of studies on the pathogenesis of IPF have been conducted, and many experimental models were generated to explore the mechanisms. However, it is yet highly questionable whether the evidence provided from the studies of IPF is applicable to the etiology of CTD-associated IP. Furthermore, it is still unclear whether the animal models such as the mouse bleomycin model can truly replicate the autoimmune progressive forms of the ILDs seen in human CTDs.
We have speculated that exploring the early immune phases of IP in the lung would be the most direct approach to understand the pathogensis before more complex secondary immune responses occur in the evolution of IP [6, 7]. PM/DM is one of the major CTD, of which the most critical problem is pulmonary involvement. As mentioned before, ILD, mainly IP, often severe and progressive, has been recognized in 30–70% of PM/DM patients and is frequently associated with a dismal prognosis. While the presence of myositis-specific autoantibodies, such as Jo-1 and activated T cell muscle infiltrates, suggests autoimmune mechanisms in the etiology of PM, the pathogenesis of the associated IP remains undefined. We encountered two cases of early-stage PM-associated IP, of which we had an opportunity of investigating the fresh lung tissues obtained by video-assisted thoracoscopic (VATS) biopsy performed for the sake of histopathological diagnosis toward treatment options. Since this is the clear and robust demonstration of the pivotal role of T cells in CTD-IP, we herein present the details of our study with two cases of early-stage PM-associated IP both suggesting that T cells contribute to the early phase of the development of IP. Lung tissue was utilized with the approval of the institutional review board.
Patient A was a 51-year-old woman with no tobacco history and no family history of lung diseases, referred to our clinic for evaluation of arthralgia and myalgia. At 49 years, the patient noticed Raynaud’s phenomenon and polyarthralgia, for which she was given low-dose prednisolone with clinical improvement. Two months before the referral, she developed polyarthralgia and myalgia. On physical examination, the patient had no skin lesions but presented with fine crackles audible on inspiration in both lower lung fields. Erythrocyte sedimentation rate (ESR) was 135 mm/hr, and C-reactive protein (CRP) level was 1.2 mg/dL (reference range: 0.0–0.4). Rheumatoid factors (RFs), speckled anti-nuclear factors (ANFs), and anti-histidyl-t-RNA synthetase (Jo-1) antibodies were positive, while anti-ribonucleoprotein (RNP) and anti-scleroderma-70 (scl-70) antibody assays were negative. Levels of lactate dehydrogenase (LDH, 798 IU/L) (reference range: 109–435), creatine kinase (CK, 559 IU/L) (reference range: 44–140), and myoglobin (120 ng/mL) (reference range: 28–60) were elevated. Muscle strength was nearly normal, but electromyogram showed myogenic patterns in the muscle groups of the upper limb girdle bilaterally. Muscle biopsy revealed lymphocyte infiltration into myofibrils and muscle atrophy, consistent with PM. Arterial blood gas analysis demonstrated a pH of 7.413; partial pressure of carbon dioxide (PCO2), 44.6 Torr; partial pressure of oxygen (PO2), 84.3 Torr; and bicarbonate (HCO3-) concentration, 28.4 mmol/L. Pulmonary function tests revealed a restrictive pattern; vital capacity (VC) was 74.8%, and diffusing capacity (DLco) was 13.44 mL/min/mmHg (67.3%). Analysis of bronchoalveolar lavage fluid (BAL) showed 75% macrophages, 15% neutrophils, and 10% lymphocytes. Human leukocyte antigen (HLA) serotypes were as follows: A2, A26, B15, Cw1, Cw9, DR14, DR8, DR52, DQ7, and DQ6. Chest radiography and chest computed tomography (CT) revealed mild, subpleural, linear, and reticular opacities in posterior and lateral areas of both lungs (Figure 2a). The patient underwent video-assisted thoracoscopic (VATS) lung biopsy for histopathologic diagnosis and therapeutic planning. Biopsy specimens from anterior basal segment (S8) and lateral basal segment (S9) of the right lower lobe revealed an early usual IP (UIP) pattern, demonstrating heterogeneous lesions with residual air spaces and early fibrotic changes, surrounded by mild alveolitis with mononuclear cell infiltrations. Based on these clinical and histopathologic findings, the patient was diagnosed with interstitial pneumonia associated with PM. She was subsequently treated with methylprednisolone pulse therapy (1 g/day for 3 days) followed by oral prednisolone (30 mg/day). Over 10 months, the dose of prednisolone was tapered to 12.5 mg/day with excellent control of progression of pulmonary lesions and myositis.
(a) Chest radiography, CT, and photomicrograph of patient A. Chest X-ray and HRCT of patient A show subpleural mild linear and reticular opacities in posterolateral lung. Lung biopsy from patient A depicts heterogeneous lesions including residual air spaces and early fibrotic changes with fibroblastic foci, mild alveolitis with thickened alveolar walls, and mononuclear cell infiltrations (hematoxylin and eosin stain, original magnification ×200). (b). Chest radiography, CT, and photomicrograph of patient B. Chest X-ray and HRCT of patient B show thickened interlobular septa with bibasilar and subpleural ground glass opacities. Lung biopsy from patient B depicts mild, homogeneous changes with partial inflammatory thickening of the alveolar wall, with granulation tissues in alveolar spaces, fibrosis, and inflammatory cell infiltrates (hematoxylin and eosin stain, original magnification ×200).
Patient B was a 43-year-old woman, a lifetime nonsmoker, referred to our clinic for arthralgia and myalgia. The patient had developed Raynaud’s phenomenon 6 months prior to this presentation. On physical examination, she had swollen fingers, with no skin rash. Fine crackles were heard on inspiration in the lower lung fields. No muscle weakness was apparent, but thorough examination revealed myositis. Laboratory data were as follows: LDH level, 616 IU/L; CK level, 410 IU/L; and CRP level, 0.4 mg/dL. Histological examination of muscle biopsy specimen showed mononuclear cell infiltrates in muscle tissue, consistent with PM. Assays for RF, anti-dsDNA antibodies, anti-Jo-1 antibodies, anti-centromere antibodies, and anti-scl-70 antibodies were negative. ANF (speckled pattern) and anti-ribonucleoprotein (RNP) antibodies were positive. Arterial blood gas analysis was unremarkable. Pulmonary function testing showed a restrictive pattern; VC, 70.6%, and DLco, 14.71 mL/min/mmHg (77.2%). BAL analysis demonstrated 67% macrophages, 11% neutrophils, and 22% lymphocytes. HLA serotypes were as follows: A24, A26, B15, B61, Cw10, DR9, DR53, and DQ9. Chest radiography and CT revealed subpleural and basilar linear and reticular opacities with ground glass attenuation (Figure 2b). Histopathological examination of lung specimens from VATS biopsy of superior (S4) and anterior basal (S8) segments of the left lower lobe disclosed a nonspecific IP (NSIP) pattern. Specimens showed mild and homogeneous changes with partial inflammatory thickenings of the alveolar wall, with granulation tissues in alveolar spaces, fibrosis, and inflammatory-cell infiltrations. Clinical and histopathologic findings lead to a diagnosis of IP associated with PM. She was subsequently given pulse therapy with methylprednisolone (1 g/day for 3 days) followed by oral prednisolone (50 mg/day), which was effective in ceasing active myositis and IP. When the dose of prednisolone had been tapered to 30 mg/day after 4 months, respiratory function testing showed that %VC and DLco had improved to 79.0% and 17.56 mL/min/mmHg (90.7%), respectively.
Immunohistochemical analysis was performed on lung-infiltrating cells utilizing biopsy specimens. Substantial infiltrations of mononuclear cells were noted in both patient A (UIP pattern) and patient B (NSIP pattern). The mononuclear cells were predominantly CD3+ T cells, accompanied by a subtle infiltration of B cells (CD20+), and a minimal number of monocytes (CD19+). Of infiltrating T cells, CD4+ cells were predominant compared to CD8+ cells in both cases. We then analyzed T cell receptor α-chain variable region (TCR Vα) and TCR β-chain variable region (TCR Vβ) repertoires of T cells infiltrating the lung tissues using an adaptor ligation polymerase chain reaction (PCR)-based microplate hybridization assay [159]. Quantitative assay has been used in many previous studies, and accuracy and reproducibility of this assay have been validated [160, 161]. Briefly, total RNA was extracted with TRIzol Reagent (Invitrogen, USA) from lung tissues obtained by VATS biopsy. Complementary DNA (cDNA) was synthesized with reverse transcriptase (Superscript II) and BSL-18E primer adaptor. Universal adaptor primers were ligated to the cDNA, and PCR was performed with the universal primer and primers specific for TCR Cα or Cβ chains. PCR products were biotinylated by amplification with 5′-biotin primer and the universal primer. The biotinylated PCR products were hybridized on microplate wells immobilized with various oligo probes specific for TCR Vα or Vβ region sequences. Finally, the amount of biotinylated product bound to each probe was measured by quantitative enzyme-linked immunosorbent assay (ELISA) with alkaline phosphatase streptavidin. The results of quantitative analysis of TCR Vα or TCR Vβ usage in patient A and B are shown in Figure 3a and b, respectively. The open column and solid column indicate the frequencies of TCR Vα/Vβ repertoires in the lung tissue and the peripheral blood lymphocytes (PBLs), respectively. We found that the usage of repertoires of TCR Vα/Vβ in the lung differed from those in PBL, with certain TCR V gene families detected more frequently from lung tissue. In patient A, TCR repertoires of VA2.1, VA8.1, VB4.1, and VB24.1 were predominantly expressed in the lung compared to PBL, while TCR V repertoires VA23.1 and VB13.1 were more frequently expressed in lung tissue from patient B. As expected, no TCR signals were detected on normal lung tissue obtained from patients without IP using the same method (data not shown).
(a) Quantitative analysis of TCR repertoires: TCR Vα gene usage (top) and TCR Vβ gene usage (bottom) in patient A. Solid and open bars indicate frequencies of TCR Vα/Vβ repertoires in PBL and lung tissue, respectively. VA2.1 and VA8.1 and VB4.1 and VB24.1 repertoires predominate in lung tissue compared with PBL. (b). Quantitative analysis of TCR repertoires: TCR Vα gene usage (top) and TCR Vβ gene usage (bottom) in patient B. Solid and open bars indicate frequencies of TCR Vα/Vβ repertoires in PBL and lung tissue, respectively. VA23.1 and VB13.1 repertoires are more frequent in lung tissue compared with PBL.
IP associated with PM/DM is recognized as a critical complication due to its association with poor disease prognosis. In this study, we investigated T cells infiltrates by analyzing the TCR repertoire usage in lung tissue in two patients with PM-associated early IP. Both patients showed marked lymphocytes aggregates, predominantly CD3+ T cells, at IP lesion sites. In addition, the analysis of TCR Vα/Vβ repertoire usage indicated a modest accumulation of T cells expressing selected TCR V-gene segments, which differed distinctly from those of PBL. These findings strongly suggest pathogenic involvement of organ-specific oligoclonal T cell accumulation in development of PM-associated IP. Since TCR diversifies with disease progression due to the phenomenon of “determinant spreading” in which autoreactive T cell responses, initiated by a single antigenic epitope, evolve into multiepitopic responses, we considered it important to perform TCR analysis from lung tissue in the earliest stage of IP [162]. Regarding differences in predominant TCR V gene usage between the two cases, we suspect this is due to HLA differences. A previous study on lung TCR repertoire in patients with PM by Englund et al. reported selective TCR V gene usage, characterized by a panel of TCR-specific monoclonal antibodies on flow cytometry [163]. However, that study used BAL fluid rather than lung tissue in which infiltrating T cells may be more directly involved in the disease process. Although we also tried to analyze TCR repertoire from BAL fluid, the data were inconclusive due to lack of TCR signals along with background noise from RNA debris. To our knowledge, this is the first robust demonstration of the presence of selective TCR V gene usage and its differential expression in lung tissues of patients with PM using both lung biopsy tissue from early IP and PBL. Because our study involved only two cases, these findings should be confirmed in a larger study. However, we believe these findings strongly suggest that T cells which are recruited into the lung may be exposed to autoantigens, selectively expanding by antigen-driven responses. Further studies are needed to identify T cell epitopes of the pathogenic antigens, which may potentially lead to the development of antigen-specific, molecular-targeted therapies, such as the induction of anergy by peptide analogues similar in structure to culprit antigens [164, 165].
Thus, as a result, the T cell receptor (TCR) repertoire study combined with histological analysis demonstrated substantial CD3+ T cell lung infiltrates with specific oligoclonal TCR usage that differed from those in PBL, suggesting a pivotal role for T cells in the pathogenesis of PM-associated IP via antigen-driven immune mechanisms.
Because of the wide variation in manifestations of ILD in the autoimmune disease of CTD, no simple management strategy is adequate for every possible clinical setting. While a part of patients with CTD-associated ILD have limited and stable disease, not always requiring treatment, the significant proportions have severe and progressive disease which necessitates prompt and appropriate treatment. Essentially, nevertheless, general therapeutic principles in CTDs can be applied to many situations including acute and chronic disease. These include use of corticosteroids, azathioprine (AZA), cyclophosphamide (CYC), methotrexate (MTX), mycophenolate mofetil (MMF), and calcineurin inhibitors [13]. Although there are no specific guidelines for the management of CTD-ILD, general strategies recommended for IPF of IIP are also often applied in some cases of CTD-ILD. Emerging treatments with effects in IPF, e.g., Pirfenidone (a pyridine showing both anti-inflammatory and anti-fibrotic effects) and Nintedanib (a small-molecule tyrosine kinase inhibitor targeting VEGF-, FGF-, PDGF-receptors) may offer additional treatment options, though the efficacy has not been evaluated in CTD-ILD [166]. Basically, in contrast to the dismal prognosis in IPF/UIP of IIP with a median survival since diagnosis of 2–3 years, clinical experience in managing patients has taught us that immunosuppressive drugs in CTD-associated ILDs are capable of benefiting a significant proportion of patients, particularly those with certain histological patterns of disease.
With regard to the clinical study, there have been only two randomized placebo-controlled trials investigating the effect of immunosuppressive treatment in SSc-associated ILD. Briefly, the Scleroderma Lung Study (SLS) and the Fibrosing Alveolitis Scleroderma Trial (FAST), evaluated CYC (given orally at 2 mg/kg for 1 year in SLS and intravenously at a dose of 600 mg/m2 monthly for 6 months, followed by oral AZA for the following 6 months in FAST) for SSc-ILD [72, 73]. Both studies found a slower decline in forced vital capacity (FVC) in the CYC group compared with placebo. Intravenous CYC elicited a lower rate of bone marrow toxicity, severe infections, and gonadal failure compared to oral administration, likely due to higher cumulative dose acquired by daily oral administration [167]. Six months after quitting of immunosuppressant, the recovery in FVC fell into baseline, suggesting the requirement of prolonged immunosuppression therapy to maintain stability of lung function [168]. However, it should be noted that, despite studies supporting the benefit of CYC therapy in preventing deterioration in the lung function and premature death in patients with SSc–ILD, recent systematic review and meta-analysis of RCTs and observational prospective cohort studies failed to validate any clinically significant improvement in pulmonary function in SSc patients treated with CYC [169, 170].
In PM/DM-associated ILD, high-dose steroid is often the first-line drug, although no definite therapeutic recommendation for the disease has been established yet. The other drugs most frequently used are AZA, MMF, hydroxychloroquine, MTX, CYC, and calcineurin inhibitors, e.g., cyclosporine A (CSA) and tacrolimus (TAC). Rituximab, anti-CD20 monoclonal antibody therapy, has lately emerged as a promising remedy of biologics in patients who have failed conventional immunosuppression treatments [171, 172]. Among a variety of immunosuppressants, the efficacy of calcineurin inhibitors for the treatment of PM/DM-associated ILD should be highlighted. CSA, which inhibits T cell proliferation and T cell-mediated cytokine productions at the transcriptional level, has begun to be used for PM/DM-ILD since the 1980s [173–175]. In 1998, the first nation-wide survey for the treatment with CSA in IP associated with CTDs was conducted in Japan, and the efficacy of a combination therapy with CSA and corticosteroids in PM/DM associated IP was indicated [176]. A number of retrospective and open-label studies have supported the benefit of CSA for the treatment of ILD with PM/DM [177–181]. Takada et al. published a retrospective multicenter study of 38 cases with acute ILD with PM/DM, whereas it was shown that the combination therapy with CSA and corticosteroids started from the early phase of ILD is superior to corticosteroid monotherapy [178]. Today, calcineurin inhibitors are widely used especially in Japan as both an induction and maintenance therapy for PM/DM-ILD, generally resulting in favorable prognostic outcomes. The appropriate serum concentration of CSA to ensure a maximal effect as well as to avoid toxicity in patients with PM/DM-ILD should reach approximately 150 ng/mL and1000 ng/mL, at trough and at 2 hours after administration, respectively [179]. Another calcineurin inhibitor, TAC, which is a 100-fold potent T cell inhibitor compared to CSA, was also introduced into the treatment for PM/DM-ILD, and its efficacy and tolerability have been demonstrated in retrospective studies and case series since the report by Oddis et al. in 1999 [182–185]. Ochi, et al. described a superior effect of TAC used in two myositis patients with progressive ILD who failed CYC and corticosteroid treatment but successfully recovered with TAC, showing significant improvement in symptoms and radiologic changes [183]. The appropriate tacrolimus trough level for the treatment of ILD in PM/DM patients have not been established by clinical trials, but it is usually set as 5–20 ng/mL on the basis of data from renal and bone marrow transplantation [186].
Given the treatment-effect heterogeneity of the lung disease observed in PM/DM, it is important to prepare novel therapeutics for the challenging cases of ILD which are refractory to conventional formulas. Recently, Suda et al. reported the effectiveness of multitarget therapy for the ILD in two cases of anti-MDA5 antibody-positive DM which is known to be associated with progressive ILD and sometimes has a lethal outcome despite strong immunosuppressive therapy including CYC [187]. They used TAC and mizoribine (MZR, an inosine monophosphate dehydrogenase inhibitor) in combination with corticosteroids. MZR is a nucleoside of the imidazole class, with the same mechanism as MMF: selective inhibition of lymphocyte proliferation by blocking inosine monophosphate dehydrogenase [188]. The safety and steroid-sparing effects of MZR have been shown in various CTDs, and the efficacy of multitarget therapy using TAC and MZR was reported for systemic lupus erythematosus [189, 190].
Despite increased recognition of CTD-associated ILD and its prognostic significance, the pathologic mechanisms that lead to the considerable pulmonary changes are not yet fully defined, and thus, the only limited progress has been so far made in the therapeutic domains. Immunosuppression therapy remains the mainstay of treatment for CTD-ILD. To generate significant advances in therapeutic intervention strategy, fundamental understanding of the pathogenesis of CTD-ILD is essential. As noted, we had an opportunity to carefully study the cases of early-stage IP associated with PM by utilizing lung biopsy tissue and PBLs. The T cell receptor (TCR) repertoire study combined with histological analysis demonstrated substantial CD3+ T cell lung infiltrates with specific oligoclonal TCR usage that differed from those in PBL, suggesting a pivotal role for T cells in the pathogenesis of PM-associated IP via antigen-driven immune responses. The results imply potential elucidation of specific antigen(s) that oligoclonal, lung-infiltrating T cells recognize, which may provide novel insights into the development of immunospecific treatments such as molecular-targeted or specific T cell-targeted therapeutics.
The authors have declared no conflicts of interest.
The authors have declared in the published articles that the informed consent was obtained from the patients.
The authors have declared in the published articles that the protocols were approved by the institutional review board.
The global economy knowshow to build nearly anything, but it does not know what to build to solve our pressing social, economic, and environmental challenges. This is evident in the persistence of problems like inequality and unsustainability. Our modern economy has not solved these problems because nearly everything we know about economics and commerce was inherited from an era of scarcity, which drives win-lose competition over money, a grow-or-die business imperative, economic disparities, and damage to the natural environment [1].
\nThis win-lose competition over money creates a dilemma. Businesses seek more customers, while people seek more of the very goods and services that businesses want to sell, with money often the only missing ingredient for commerce to occur, even though we invented money to promote needed commerce. At the same time, many people have useful skills for community economic development, with no way to put those people to work because of a lack of money to make that happen. This “lack of money” dilemma hits economically disadvantaged communities especially hard, and increases the challenges of closing economic disparities.
\nWhile this dilemma is accepted as normal by economists—as well as by business, community and government leaders—it makes no sense. These problems may seem solvable by issuing more money, but the more we issue money, the more competitive startups and businesses grow, generating more downward pressure on each enterprise’s market share, prices, and profits. It also impacts employee wages, which affect family purchasing power [2].
\nModern economies have more wealth producing ability—measured in underutilized capacity – than the money to distribute it. Many of our economic problems—from affordable housing and healthcare to world hunger and clean water to education, training and employment—can be solved not by issuing more money, but by questioning the assumption that win-lose competition over money is the most efficient way to provide the greatest economic good for the greatest number. Turning currently underutilized business capacity into profitable production and sales—at the marginal cost of production—is the win-win foundation for a needed update to free-enterprise economic thinking.
\nUnbridled competition over money is a double-edged sword. Free-enterprise competition is a powerful engine of economic growth. It increases customer traffic to a given destination, while improving consumer choice, quality and service, all while holding down prices. Competition is also our model for economic growth, creating jobs and expanding the tax base by rewarding entrepreneurs for hard work, risk and innovation. However, extreme competition over money puts downward pressure not only on a company’s ability to perform, but also on employee wages, which stall or decrease when unbridled competition increases. That creates a large and growing gap between what a normal economy can produce and what employees, families and communities can afford to buy with their artificially restrained wages.
The cycle of innovation, growth, maturity and decline applies to most products and industries, and is well understood. The hidden anomaly is that our wealth-producing capabilities constantly improve with advances in technology, infrastructure and human skill, knowledge and creativity. Yet the standard of living and quality of life go up and down with the money-driven boom and bust cycles of the business cycle. Economists insist that falling prices benefit everyone in the end, and that new jobs created by ongoing innovation replace old jobs that are lost. Yet, downward pressure on market share from local-to-global proliferation of competitive duplication causes the growth of excess or underutilized business capacity, creating wasted wealth [3].
\nThis wasted wealth stems from a flaw in how we think about and use money. We have made money the object of competition and the goal of the economic game. The simple yet mysterious fact is that economics, commerce and the popular culture all confuse money (our tool of wealth creation) with wealth (the goods and services). Of course, money is a critical tool in the equation, but it should not itself be the objective of economics. This confusion of money and wealth begins to explain our seemingly intractable social, economic and environmental challenges, even as all the other factors of production are only improving rapidly [4].
\nConfusing money and wealth is akin to confusing a map with the terrain the map represents. Economics will take a great leap forward when we distinguish money from wealth and introduce a next generation of money to mobilize real and available economic wealth wherever the dollar fails to do so. This is an enormous business opportunity, because there is so much untapped wealth in the world, side-by-side with so much unmet need. This serves no one: not businesses, individuals, communities, or society. This is not just an issue for the poor. Many individuals and families are just a paycheck or a layoff away from dire economic circumstances.
\nThis is a societal problem, not a personal failing; it reflects a repairable shortcoming in our free enterprise system. And no one is to blame for this: not the rich, the poor, the banks, foreign competition, the government, the political left or right, or human nature. We all suffer from outmoded ways of thinking and outdated economic tools and practices. Blaming one group or another - all of them equally caught in a system they did not invent - gets in the way of a solution.
\nIf we look across the economy, it is overflowing with excess productive capacity. College desks are empty more than they are full; restaurant tables are empty more than they are full. There are extensive off hours at fitness clubs, movie theaters, oil change shops, beauty salons and elsewhere. We are living in a world of wasted capacity and yet we are already overbuilt to meet the needs of everyone on the planet. For example, food is an abundant renewable resource, yet people go hungry across the world. Meanwhile, global agrobusiness is one of the most powerful industries on the planet and they want more customers. Business wants more customers and people need more goods and services, and yet, while humans invented money to match buyers with sellers and work to do with people who need jobs, all that’s missing is money [5].
\nThe automotive industry offers another example of excess capacity. While numerous people are driving old and perhaps dangerous vehicles, and others can afford no vehicle at all, thousands of auto dealerships are awash in high quality new and used cars. Only money or purchasing power is missing to match eager sellers with eager buyers. The same is true of education. While there is much agreement on the need for a more educated workforce, we do not know how to make college education affordable for all. Many people, young and old, desire a college education that they simply cannot afford (and affordability is a money issue not a wealth production and distribution issue). Colleges and universities have enormous numbers of unfilled desks and compete for student tuition dollars. For the most part, they each have enough infrastructure, instructors and staff to serve many more students, and could easily increase teachers and staff if a source of funding was available for everyone who wants to go to school. Scholarships are a means of discounting tuition, yet many youth leave college saddled in debt—again a money issue!
\nThe hidden lessons of the 2008–9 US housing market crash and subsequent global economic downturn are revealed in the movie The Big Short [6]. The movie ends with three revealing statistics: in the US alone, $5 trillion in wealth disappeared; 8 million people lost their jobs; 6 million families lost their homes. We also know that many millions of people lost some or all of their life savings and large numbers of businesses failed. Why are these well-known figures critical for repairing the US and global economies? Because the simple fact is that no real wealth disappeared: no buildings, no technology or global economic infrastructure, no labor skill, management knowhow or human creativity disappeared, no products disappeared off retail shelves, and not a single ounce of materials or a joule of energy disappeared. So what disappeared causing the devastating economic consequences on people and communities?
\nTechnically, only valuations fell. Valuations are the price in dollars that one might expect to receive when selling stock, a company, a home, or other real and valuable material assets. In other words, during an economic downturn, numbers in computers, called money or stock, shrink. Nothing in the material world that constitutes wealth nor any of the factors of production, described above, disappear or diminished. In fact, the factors of production continue to improve during economic downturns, which ultimately help to set the stage for eventual recoveries. In truth, once again, only money goes missing to put people back to work and turn idle productive capacity into new consumable wealth for society.
\nThis is, in part, what makes life in the modern world so stressful. Advances in technology cause us to chase money at an ever-increasing rate, rather than allowing us to enjoy time in nature, family and community time, personal growth and development time, religious and spiritual time, and so forth. It is outside our sense of possibility that technology could do the lion’s portion of the work, leaving people to enjoy ever-shorter working hours by sharing what is left. Instead, people are today chasing after a living at the ever-increasing, 24–7-365 pace of technology. And we are paying the price with our health, and the health of our families, workplaces and communities. Technology could eliminate most repetitive, boring, and dangerous work, allowing people to enjoy life more. Why instead are ever-growing numbers of people feeling anxious about their economic futures and depressed about their situations? Put bluntly, the dynamics of the economy have hard-wired us to chase money for survival (and, of course, for many to get ahead).
\nAs a solution to the dilemma of businesses with desirable goods and services existing side-by-side with eager customers lacking purchasing power, we propose creating a next generation of money—backed by the underutilized wealth of society—to stretch purchasing power in fiat currencies beyond what is available today. Fiat currencies have a critical role to play as a means of exchange, but a single currency does not efficiently distribute both what is abundant and what is scarce. A new accounting protocol can stretch current financial resources to distribute evermore available wealth. Pairing the dollar with a second currency, as a measure of wealth, addresses this dilemma, expanding production and distribution for what is already or could easily be in sufficient supply, e.g., food, shelter, healthcare, education, and so forth. In such a system, the ratio between dollars and the second currency in the price of an item would denote its relative scarcity or sufficiency.
\nConsider how the sharing economy accomplished rapid economic growth when mobile apps and social media had a fraction of the economic impact that they have today. A decade ago, it exploded onto the scene creating millions of jobs and billions of dollars of new wealth. On the one hand, the sharing economy demonstrated how to capture, monetize and distribute the excess productive capacity of solopreneurs—an empty room in someone’s home or an idle car and driver. On the other hand, filtered through win-lose competition over money, someone had to take the hit for all this economic growth. Hotels, motels and their employees took the hit from the rise of Airbnb, while cab drivers, limo drivers and their companies took the hit from the rise of Uber and Lyft. This showed how the outdated economics of scarcity, based in win-lose competition over money, can stifle efforts to monetize excess capacity.
\nWe need, instead, to move toward “Continuous Economic Improvement”, where every advance in the factors of production—technology; infrastructure; human skill, knowledge and creativity; our ever-growing access to nature’s abundant and free renewable resources—raises the standard of living and quality of life for everyone, shortens working hours across-the-board and, ultimately, eliminates traditional economic growth and creates a Circular Economy.
\nWhen we monetize excess capacity, as in the sharing economy, not with dollars, since the lack of dollars has created the problem to begin with, but with another measure of wealth, a second currency, we can address the paradox of our having excess wealth and insufficient cash. It also enables us to close disparities, whether it’s for women or communities of color or youth, which is hard to do in a cash economy because of a lack of dollars. In a dual currency system, if somebody pays you in the second currency, you can pay for things on a part cash/part second-currency basis, stretching your purchasing power and get more of what you need.
\nThe traditional approach to closing disparities include: local, state and national government programs; philanthropy and volunteerism; corporate social responsibility and social entrepreneurship; cooperative enterprises; women and minority owned businesses; public education campaigns; wellness campaigns; green products and services; microlending; collective impact initiatives and so forth. Just as millions of businesses compete over market share with their products and services, millions of government agencies, schools and community programs compete for tax allocations, and millions of non-profit and community organizations compete for philanthropic funding and volunteer time. In the end, this proliferation of competitive duplication within and across sectors creates immense inefficiency. Greater efficiency is at the heart of economic progress and environmental sustainability.
\nContinuous Economic Improvement would operate not by holding down production to the level of available purchasing power, but by raising the purchasing power for individuals, families and communities by capturing he ever-increasing productive capacity in the world. In order not to disrupt what was already working well in the economy, Continuous Economic Improvement would not raise employer labor costs, increase taxes or increase debt. It has three cornerstone premises:
Business innovation and the profit motive is more effective than politics to solve social, economic and environmental challenges. When joined with institutional power and resources and community wisdom and mobilization (empowered by social media and other modern information technologies), it would be an unstoppable force for the common good.
Modern technology, global economic infrastructure, renewable resources and eco-sustainable business practices can now produce more than enough food, housing, education, healthcare, travel and entertainment options for everyone on the planet to enjoy a high quality of life and a healthy balanced lifestyle.
Money, commerce and citizen empowerment could be immediately brought into the 21st Century with another step in the history of money innovation. We would go from barter to coins to paper currency to electronic commerce to ledgers as part and parcel of economic history.
An economics based on ledgers recognizes that transactions that once involved exchanging tokens – cash and coins – are now increasingly done through credit and debit cards, which amounts to digital bits moving from one ledger to another. This represents a transformation in the history of money. Unlike cash and coin tokens, ledgers do not crash or inflate in value, do not experience scarcity or hoarding, and do not lend themselves to speculation or theft. Moreover, ledgers allow us to measure not just the exchange of cash, but other currencies as well, accounting not only for money, but also for other forms of capital that we have not tallied before [7].
\nThe role of ledgers as a measure of untapped wealth has broad implications for many of the chronic challenges we face. Impoverished communities, for example, may lack money, but they often have extraordinary amounts of social and cultural capital, which, if accounted for, can enable these communities to address their own problems and meet their own needs without depending upon government programs or non-profit charity. Ledgers also enable us to have economic activity that does not destroy the natural environment in the process by accounting for work that has environmental benefits as equally as that which does not. Likewise, ledgers provide a way for businesses that have excess capacity and owners who have under-utilized goods and services to put those assets to work meeting the unmet needs of customers and consumers.
\nLedgers measure wealth, while U.S. dollars – and the national currencies in other nations –remain primarily units of exchange. But there are also other features that distinguish these two types of currencies. A ledger currency – let us call them Ledger Dollars (L$) – could stretch U.S. dollars through dual currency transactions. For example, a $20.00 restaurant meal might cost $12.00 and L$ 8.00, much like the economics of senior discounts or ‘2 for 1’ dining. Or a $20 fitness club pass might cost $4.00 and L$ 16.00, based on the much lower marginal cost of production at a club than at a restaurant.
\nBank-issued dollars – or other national currencies – are government money, backed by debt and taxes. Ledger Dollars are more like loyalty rewards (frequent flyer miles, Hilton Honors, Starbuck Points, etc.) which are business-issued currencies backed by real business products and services. But unlike loyalty rewards, L$ are not rewarded for consumer spending and do not promote the competitive advantage of one business over another. National currencies are scarce by their very nature and therefore they command interest and dividends in the market. They are also party to the ups and downs of speculation and part-and-parcel of inflationary and recessionary problems as well. In contrast, Ledger Dollars are purely symbols—mere entries in a ledger—used to match production of goods and services with business, employee, customer, family and community wants and needs. There can never be a shortage of symbols—inches, gallons, pounds or numbers— to get needed work done in communities. And through the efficient match of customer purchasing power to available products and services, we can finally solve the pesky problems of inflation and recession.
\nU.S. dollars or other national currencies are a blunt instrument to address economic inequity, as traditional money chases the highest rate of return and as interest and dividends bring evermore money to those who already have money. Ledger Dollars, instead, encourage a more level economic playing field through smarter production and distribution of real wealth. Finally, U.S. dollars encourage consumerism to promote traditional economic growth, which has negative social and environmental consequences. In contrast, Ledger Dollars promote a higher quality of life by engaging everyone in greater economic efficiency and voluntary sharing of currently idle resources, advancing better living, with less consumption [8].
\n\nTraditional Economics and Commerce versus\n \nDual Currency Commerce and Ledger Economics\n | \n||
---|---|---|
\nCategory\n | \n\nFiat-based Economic\n \nand Commerce\n | \n\nDual Currency Commerce\n \nand Ledger Economics\n | \n
Philosophy | \nCompetition over scarce resources—in the face of unlimited wants and needs—creates the greatest good for the greatest number. | \nPeople and planet-centered economics and social entrepreneurship. Breaks no laws of free enterprise economics; fiat/dollars distribute what is scarce; Ledger Dollars distribute what is sufficient/abundant. Business-led, market-based, profit driven, yet immediate not trickle down. | \n
Economic Driver(s) | \nMaximize shareholder value through increased profits (not a bad thing, just an incomplete approach) | \nTriple bottom line: people, profits, planet; seeks an equitable win for all stakeholders, while protecting the environment | \n
Currency Innovation | \nNot a field of economics; latest design innovation was paper tokens to digital tokens riding banking and Automated Clearinghouse (ACH) ledgers | \nTransitions economics and commerce from solely using a fiat token currency to a dual currency combination of a fiat currency and a ledger currency | \n
Economic domain(s) | \nRevolves around what is measured in fiat currency | \n3 domains: fiat economy; non-fiat monetized economy; unrecognized and nonmonetized excess productive capacity economy | \n
Price setting | \nSupply and Demand sets prices in fiat currencies only leaving extensive underutilized productive capacity side-by-side with extensive unmet needs | \n\n
| \n
Competition vs. Cooperation | \nCompetition over money leaves wealth on the table and drives win-lose results | \nDual Currency Commerce balances competition and cooperation to lift everyone up together | \n
Impacts of labor-saving technology, outsourcing, mergers and acquisitions | \nMany people lose their jobs, while other people are left working longer and harder. | \nAdvances in technology and sharing work globally raises everyone’s standard of living and quality of life, while shortening working hours, and reducing damage to the natural environment | \n
Quality of life considerations | \nDrives longer working hours and business versus labor workplace dynamics; degrades the natural environment; social issues (crime, workplace stress, addiction) are considered “personal problems” | \nContinuous economic improvement drives: ever-higher quality of life; ever-shorter working hours; ever-less damage to the natural environment by thoughtful and cooperative distribution of work, material sufficiency, and leisure; social problems (crime, workplace stress, addictions) are addressed as social issues | \n
Diversity, Equity and Inclusion | \nDisparities remain and expand because fiat money seeks the highest rate of return and results in money flight from communities | \nDisparities become relatively easy to close at the marginal cost of production through the monetization of excess productive capacity | \n
Governance | \nGovernment banking regulations and one-size-fits-all civil legislation | \nGovernance by protocol (akin to the Internet, Visa/MC, and the 12 Step program of Alcoholics Anonymous). Algorithms govern currency distribution based upon available resources. Mass customization allows all network stakeholders to determine rules and regulations within customized communities | \n
Relationship to growth | \nBased on consumerism and the inherited “grow-or-die” business imperative | \nSeeks to build a Circular Economy with a values-based economic engine; recognizes extensive underutilized productive capacity and replaces growth imperative with efficiency; does not need consumerism, so focuses on quality-of-life considerations | \n
Healthcare | \nFocus is on institutional care and treatment, not prevention; highly profitable activities include: treating cancer and diabetes; diagnostics and pharmaceuticals; cardiovascular medicine (a heart attack is a major economic event, while quitting smoking lowers the GDP) | \nFocus is on individual, family and community health and wellness through addressing the Social Determinants of Health and Health Disparities. Wellness investments are low-cost, including healthy diet, moderate exercise, economic stability and wellness education, etc. | \n
Ledger economics represent a paradigm shift in how we think about money and look at wealth. Consider that nothing in the physical universe changed when human perception shifted from the earth at the center of the universe to the sun at the center of the solar system. Yet, that shift in perception opened the door to enormous advances in science and society. Using the solar system as a metaphor, money has long stood at the center of society’s economic universe. This has led us to subordinate all that we do to the availability of money, including much that communities value: families, education and healthcare, God and spirituality, hobbies, healthy balanced lives, culture, the natural environment and more.
\nLedger Dollars put those values, rather than cash, at the center of the economic universe. Money should revolve around values and not the other way around, especially since money is just a means to our ends, something that we designed and that we can redesign if it no longer helps us achieve what we most value. The redesign of money may sound odd, but we have done this before, innovating new tokens of exchange when necessary.
\nHistorically, money innovation has been technology-driven, following the accelerating pace of economic evolution. In the 1800s, the United States transitioned from gold and silver coins to paper currency, as the dominant form of money. During that time, virtually every state and every bank issued their own paper money. The system was unworkable, and thousands of banks failed. In response, the equivalent of an industry standard was set for paper currency. It consisted of a single national currency and a Federal Reserve System. Then, a hundred years later the phenomenon was repeated.
\nIn the early years of the credit-card-industry banks, department stores, gas stations and others each issued and processed their own credit cards. The young industry had operating losses of tens of millions of dollars. An industry standard was set that provided workability and profitability for the banks. It was the VISA platform (followed quickly by MasterCard) [9]. We can learn a great deal from the standard that was set, because it included a new financial instrument (the electronic debit and credit), a new payment platform and a cooperative network of banks and retail merchants. Virtually everything proposed here can be created rapidly through a cooperative network made up of banks (and the payment systems industry), retail merchants and cardholders, which was the original vision of VISA’s Founder. Money innovation has also enabled the democratization of wealth:
The agricultural era brought the transition from bartering to gold coins over a 3,000 to 5,000 year period, with coins made possible by the technologies of smelting and metal casting
The industrial era, over a period of 300 to 500 years, saw the transition to paper currency and checks, all made possible by printing and paper making
Today’s high-tech global era, fueled by the transition to electronic banking, credit cards, e-commerce, and now mobile apps, has matured over a mere 30 to 50 years, all made possible by computers, plastics, and the Internet.
That increasing pace, from millennia to centuries to decades, has demonstrated not only the growing rapidity of money innovation, but also its feasibility as a way to address unmet needs. And if that pace continues, we think that it could be just a matter of 3 to 5 years to see the emergence of a monetary system that revolves around and supports what communities most value: a second currency, enabled by mobile apps, social media and blockchain and able to absorb excess assets, compensate voluntary work, and increase the quality of life of everyone.
\nWe cannot solve society’s greatest challenges with a tool – money – that is insufficient for the tasks we want it to do. But this is not impractical or overly idealistic at all when you realize that society operates at only a fraction of its social, economic and environmental potential. We have all the tools that we need to make a rapid and sustainable economic transformation happen and a universally high quality of life available to everyone.
\nOver 70 years ago, with no computers or global economic infrastructure - and with only on-the-job training for the so-called unskilled members of society - the U.S. went from the depths of the depression to full employment and global war production in a mere 18 months. The three key ingredients of this extraordinary economic feat were a common cause, a funding source, and a cooperative mobilization in contrast to everyday competition over money. A common vision, modern technology, a new wealth accounting protocol, and cooperative mobilization could enable a 21st century ledger-economic system that works at the pace of mobile apps and social media.
\n\nLedger Dollars integrate the best features of many popular currencies\n | \n||
---|---|---|
\nMoney Type\n | \n\nMost useful features\n | \n\nLeast useful Features\n | \n
\nFiat/national currencies\n | \n\n
| \n\n
| \n
\nBarter\n | \n\n
| \n\n
| \n
\nLoyalty\n \nRewards\n | \n\n
| \n\n
| \n
\nCommunity Currencies and Time Dollars\n | \n\n
| \n\n
| \n
\nCryptocurrencies\n | \n\n
| \n\n
| \n
\nAnticipated results by combining the best features of multiple currencies and platforms\n | \n||
\nLedger Dollars used within a Dual Currency Ledger Economics Network\n | \n\n
| \n
The Dual-Currency Ledger-Dollar (DCLD) system has four main stakeholder groups: Individuals, Merchants, Sponsors, and System Operators.
\nIndividuals download the DCLD app and receive a first monthly dividend on their smart phones or other digital device. The app reveals where to earn and where to spend Ledger Dollars. It helps people to find community organizations, schools, employers and government agencies offering L$ to volunteers, students, employees, and government benefit recipients who seek to earn additional Ledger Dollars above their monthly allocation. For participants in the system, it not only has the tangible benefit of increasing their purchasing power at participating merchants, but also intangible advantages like feeling valued for contributing to thriving communities, meeting like-minded people, and helping create a better world that works for everyone.
\nSponsors are the community-oriented organizations that aggregate and report the rewardable activities of network participants. A public school, for example, could reward parents or local residents who tutor struggling students. It could also reward those students for putting in the effort to improve their academic performance or engage in service learning in the community. Employers would do the same for participating employees who join company volunteer groups, wellness teams or green teams. Community organizations reward volunteers. Healthcare systems reward patient compliance, donating blood, and better health outcomes. Government agencies distribute L$ to benefits recipients. Indeed, any socially valuable activities can lead to earning extra Ledger Dollars. In this way, Sponsors can improve volunteer recruitment and retention, advance community wellbeing, increase their impact, attract funder attention and support, and reward the engagement of their own employees.
\nMerchants determine the ratio of U.S. dollars to Ledger Dollars to accept and any restrictions on when they will accept the second currency. Merchants benefit by increasing the number of customers, while selling targeted excess capacity at the marginal cost of production plus an incremental cash profit. They pay a modest marketing fee on dual currency sales and receive useful demographic data on community participation, free L$ employee benefit, and excellent community PR.
\nSystem Operators include payment processors and merchant services organizations; consultants to the private, public, nonprofit, cooperative, and social impact sectors; algorithm architects who see that the L$ supply makes a good match between monetized excess capacity and unmet family and community needs and others who help to aid the transition from a dollars-only economy to a dual-currency ledger system.
Stakeholder Benefits in a Dual CurrencyLedger Economics Network (DCLEN) | \n|
---|---|
\nIndividuals\n | \n\n
| \n
\nMerchants\n | \n\n
| \n
\nSponsors\n | \n\n
| \n
\nSystem Operators\n | \n\n
| \n
Sonya is a nurse in a community clinic who hears about recovery dollars from a coworker. She downloads the mobile app and receives a first monthly dividend of L$ 100.00. That dividend is determined by an algorithm based upon the volume of merchants in the network and their redemption patterns: The more merchants who join and the more people seek their products and services, the larger the dividend grows to over time.
\nUsing the merchant directory and location map, Sonya finds a local gym where a standard $99.00 membership now costs her $50.00 plus L$ 49.00, which would be akin to the gym offering a 50% discount to attract new members. This stretches Sonya’s cash and brings in extra revenue to the gym, given the low marginal cost of accommodating another customer on underused equipment and facilities.
\nEager to earn more recovery dollars, Sonia uses the app to locate community sponsors who could use volunteers. When she spends two hours a week volunteering with a sponsor in the network, Sonya earns L$ 20.00/hour, which adds an additional L$ 160.00 per month to her account. Sonya also finds that a local food co-op allows customers to pay 10% of their total shopping bills in recovery dollars, which not only increases their purchasing power, but also builds a more cooperative economy by incentivizing customers to volunteer.
\nOn the weekend, Sonya notices that the app continually highlights new merchant offers in her neighborhood and she finds a “L$ Deal” at a hair salon (shampoo and cut for $30.00 and L$30.00 for new customers). She meets some of her volunteer friends at a restaurant where their $80.00 tab is $55.00 and L$25.00 (tax and tip in cash). Sonya also donates L$20.00 to a teen group raising money for a local sports team. Spending L$ help her save cash on every day purchases and support her favorite causes from the savings.
\nThe system can also incorporate a feature to help close social and economic disparities without resorting to tax dollars. A bit like rounding-up for a cause or paying-it-forward at the drive-through, economically well-off participants voluntarily pay further up the US dollar side of Dual Currency transactions, making it possible for economically disadvantaged participants to transact in fewer dollars and more Ledger Dollars. For example: on a $20.00 meal that was priced at $12.00 and L$8.00, a more financially well-off person can voluntarily pay $18.00 cash and L$ 2.00 (or tithe and pay $22.00), which would allow a lower-income person, to pay $6.00 cash and L$ 14.00 for their $20.00 meal. In both cases, merchants gets the dollars that they contracted for, but unlike when everyone pays the same price, some people voluntarily pay with more cash allowing others to pay with more Ledger Dollars. This is a market-based, people-helping-people model that could grow up and reduce the need for so many tax-funded government programs.
\nOne use of currently wasted wealth is intended to increase employee compensation without raising cash labor costs for employers. The process improves employee wages and benefits by utilizing empty restaurant tables, off-hours at fitness clubs, excess retail inventory, and so on. Instead of downsizing companies to match money-based demand in the market, it raises people’s purchasing power up to the level of available business capacity.
\nMany employers know how to use a portion of their excess capacity as a perk or a benefit for their own employees. Employees who work for an airline enjoy free or discounted flights. Those who work at universities generally enjoy free or discounted classes. Fitness club employees enjoy free or discounted memberships, while restaurant employees enjoy free or discounted food. This is true across the private sector, as well as in the public sector (public universities) and the nonprofit sector (YM/YWCAs). It is noteworthy that if businesses operated at full-capacity, with 100 percent cash customers, this common form of employee benefits would not exist, confirming the existence of underutilized business capacity.
\nLedger economics makes the excess capacity of employers available to all employees as a perk or benefit for working within a network of cooperating businesses, government agencies and nonprofit organizations. Imagine the pooling of all this excess capacity into a “virtual community warehouse” for sustainable economic development, accessed not only by employees, but also by all those earning rewards within the community.
\nThe warehouse would be virtual because none of the products need to be purchased in advance or stored somewhere special, as with traditional bricks-and-mortar retail. Instead, they remain where they are normally produced and sold—at the airlines, the university, the fitness club or the restaurant. This system simply captures currently underutilized business capacity to offer people new purchasing power, to attract more customers, and to give communities new economic resources.
\nThe free-enterprise system manages excessive competition, easily and without government regulation, by setting needed standards across any given industry. Capitalist countries have yet to apply this principle to proliferation of competitive duplication within the economy, whether at the local, state or national levels. Why set industry standards? Consider how impractical it would be if there were 15 different types of electrical outlets to accommodate 15 different styles of electrical plugs on consumer products. To avoid this mess, an industry standard is set to which all manufacturers of both electrical outlets and consumer products adhere. The same is true of Internet Protocol on the World Wide Web, which did not require government regulation, but instead grew out of collaborative development and agreed upon design principles.
\nThe virtual warehouse would work in the same way. The participating merchants would establish a standard that everyone would agree to follow as part of the mobile app, with instructions to participating customers and sponsors on how to access the excess capacity and how to document the community hours that volunteers have donated in exchange for additional recovery dollars. When everyone has something to gain from a system, the participants involved in it have a strong incentive to agree on an industry standard so that all can benefit.
\nWill people have to pay income taxes on the Ledger Dollars they receive as a dividend or earn through their community work? While it is not possible to know the answer ahead of a formal ruling, there are useful precedents. Since the merchant is simply taking less cash and not keeping and spending a circulating currency, then Ledger Dollars are clearly not a barter dollar. Barter dollars are considered commercial in nature and taxable (with taxes due in US dollars). This system operates, instead, like a universal employee discount network, and discounts are not taxable income.
\nLedger Dollars are similar to the discounts that employees enjoy from their own employers’ excess capacity: discount flights for airline employees, discount classes for university employees, discount meals for restaurant employees, etc. And by awarding Ledger Dollars to volunteers and others, participating employees and non-employees benefit from discounts at businesses everywhere in the network. A third precedent is a community currency know as Time Dollars [10]. Time Dollars are a people-helping-people, noncommercial, community economic development currency, and they are not taxable as income. There was a ruling many years ago by the Minnesota Department of Revenue that state welfare recipients who earned Community Service Dollars (a predecessor currency) through volunteerism would not have their welfare benefits reduced, which is one more positive precedent.
\nWhile cryptocurrencies are taxable if there are capital gains from the sale of an investment in crypto, Ledger Dollars, taken off the books as soon as they are redeemed, is not an investable or speculative instrument, which is yet another reason why Ledger Dollars might not be taxed as income. Ultimately the issue is not whether this second currency will be taxable, but rather how much can this system upgrade the economy and help to create a universally high quality of life. A mature system could fund many of the community economic development needs that taxes are used for today, with the idea that an ever-more efficient economy will result in less need for government services paid for through taxation.
\nThe factors of wealth production are all at hand and continuously improving: technology, global infrastructure; human knowledge and creativity, innovative business models, access to the earth’s free and abundant renewable resources. Yet large numbers of people in the US and around the world still face a low and/or deteriorating quality of life. This can be seen in poverty and widespread economic insecurity, poor public health and safety, workplace stress, social and economic disparities, crime, addictions, youth at risk, pollution, and so forth… all of it based on an outdated paradigm of economic scarcity. We can immediately begin to move beyond all of these age-old problems by recognizing the enormous amount of untapped wealth that exists in the world and leveraging it to everyone’s advantage. Once we see that we are drowning in wealth, while searching for money (our own invention), we can begin to create more sensible and sustainable economies the world over.
\nIf, in fact, our inherited framework for economics—scarce resources and unlimited wants and needs—is outdated, then so, perhaps, are other theoretical and practical inheritances from that earlier era where that framework came from. Today’s cultural obsession with blaming the rich, the poor, the right, the left, the military, foreign competition and the like prevents thoughtful and intelligent discourse toward new solutions. A common vision of Continuous Economic Improvement for all can transcend the current left-versus-right polarization and the tendency to blame anyone, when in fact this inherited system is overdue for a 21st Century update.
\nLedger economics can help us call a truce between the political left and right and the stalemate that prevents innovative solutions from emerging. For Conservatives and Libertarians, ledger economics is completely voluntary and self-funded, as well as business-led, market-based, and profit-driven. For Liberals and Socialists, it offers immediate rather than trickle down benefits and environmentally sustainable rather than growth-based commerce, while closing rather than increasing disparities. By combining this new financial resource with a mobilization of business-community stakeholders, we can end the blame and create a dual-currency, ledger-based, equitable-and-sustainable economy, based on continuous economic improvement [11].
\n\nEconomics and Politics beyond Left–Right-Compromise\n | \n|
---|---|
\nFor Conservatives and Libertarians\n | \n\nFor Liberals, socialists and greens\n | \n
\n100% voluntary: No forced participation by government or other authorities; breaks no rules of free enterprise economics | \n\nImmediate not trickle down: the available underutilized business community resources | \n
\n100% self-funding: no need for higher taxes or deeper debt to raise everyone up with the engine of dual currency efficiency | \n\nEquitable: closing disparities through the mobilization of massive underutilized productive capacity is rapid and inexpensive rather than attempting to close disparities with ever elusive fiat resources | \n
\nBusiness-led, market-based and profit-driven: Dual Currency Commerce is purely a social entrepreneurial business innovation entering the market making use of new technologies to create greater efficiencies | \n\nEcologically sustainable: there is no need for traditional growth when the world is already overbuilt to meet all need across the planet. For example, short-term, food is an abundant renewable resource and global agribusiness wants more customers. This is purely a matter of money and will; not at all about skills, infrastructure, lack of demand, etc. Long-term, we can make communities everywhere self-sustaining and interdependent through shared technologies and sustainability best practices. | \n
\nFor everyone\n \nMass Customization: There is no need to fight and suffer over who gets their way regarding controversial issues. The Internet demonstrates that in the high-tech era, a shared platform can also allow everyone to pursue their own interests. In the same way that porn-blocker can be applied to a phone, a computer, or a television, communities of common values can voluntarily choose to participate in customized economies that are “for or against” abortions, drugs; marriage equality; guns; vegan lifestyles; prostitution, and so forth. Why? Because akin to the Internet, if you are willing to follow the protocol to get on, you can do what you want whether it is: e-commerce; pornography; charitable fundraising; art; sports; pro or against environmentalism, free speech, etc. | \n
You have been successfully unsubscribed.
",metaTitle:"Unsubscribe Successful",metaDescription:"You have been successfully unsubscribed.",metaKeywords:null,canonicalURL:"/page/unsubscribe-successful",contentRaw:'[{"type":"htmlEditorComponent","content":""}]'},components:[{type:"htmlEditorComponent",content:""}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5239},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15810}],offset:12,limit:12,total:118377},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"10231",title:"Proton Therapy",subtitle:null,isOpenForSubmission:!0,hash:"f4a9009287953c8d1d89f0fa9b7597b0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10231.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10652",title:"Visual Object Tracking",subtitle:null,isOpenForSubmission:!0,hash:"96f3ee634a7ba49fa195e50475412af4",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10653",title:"Optimization Algorithms",subtitle:null,isOpenForSubmission:!0,hash:"753812dbb9a6f6b57645431063114f6c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10653.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10655",title:"Motion Planning",subtitle:null,isOpenForSubmission:!0,hash:"809b5e290cf2dade9e7e0a5ae0ef3df0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10655.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10657",title:"Service Robots",subtitle:null,isOpenForSubmission:!0,hash:"5f81b9eea6eb3f9af984031b7af35588",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10657.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10662",title:"Pedagogy",subtitle:null,isOpenForSubmission:!0,hash:"c858e1c6fb878d3b895acbacec624576",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10662.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10673",title:"The Psychology of Trust",subtitle:null,isOpenForSubmission:!0,hash:"1f6cac41fd145f718ac0866264499cc8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10673.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10675",title:"Hydrostatics",subtitle:null,isOpenForSubmission:!0,hash:"c86c2fa9f835d4ad5e7efd8b01921866",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10675.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Topology",subtitle:null,isOpenForSubmission:!0,hash:"85eac84b173d785f989522397616124e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10678",title:"Biostatistics",subtitle:null,isOpenForSubmission:!0,hash:"f63db439474a574454a66894db8b394c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10678.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10679",title:"Mass Production",subtitle:null,isOpenForSubmission:!0,hash:"2dae91102099b1a07be1a36a68852829",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10679.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10689",title:"Risk Management in Construction",subtitle:null,isOpenForSubmission:!0,hash:"e3805b3d2fceb9d33e1fa805687cd296",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10689.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:18},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:20},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:202},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5249},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"292",title:"Material Science",slug:"technology-material-science",parent:{title:"Technology",slug:"technology"},numberOfBooks:7,numberOfAuthorsAndEditors:88,numberOfWosCitations:44,numberOfCrossrefCitations:34,numberOfDimensionsCitations:61,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"technology-material-science",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10045",title:"Fillers",subtitle:null,isOpenForSubmission:!1,hash:"aac44d6491e740af99bec2f62aa05883",slug:"fillers",bookSignature:"Emmanuel Flores Huicochea",coverURL:"https://cdn.intechopen.com/books/images_new/10045.jpg",editedByType:"Edited by",editors:[{id:"206705",title:"Dr.",name:"Emmanuel",middleName:null,surname:"Flores Huicochea",slug:"emmanuel-flores-huicochea",fullName:"Emmanuel Flores Huicochea"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8188",title:"Ion Beam Techniques and Applications",subtitle:null,isOpenForSubmission:!1,hash:"4f212072e7141ba20788b6fe79d28370",slug:"ion-beam-techniques-and-applications",bookSignature:"Ishaq Ahmad and Tingkai Zhao",coverURL:"https://cdn.intechopen.com/books/images_new/8188.jpg",editedByType:"Edited by",editors:[{id:"25524",title:"Prof.",name:"Ishaq",middleName:null,surname:"Ahmad",slug:"ishaq-ahmad",fullName:"Ishaq Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6737",title:"Powder Technology",subtitle:null,isOpenForSubmission:!1,hash:"65211e3ea1db91e795908df350115d1f",slug:"powder-technology",bookSignature:"Alberto Adriano Cavalheiro",coverURL:"https://cdn.intechopen.com/books/images_new/6737.jpg",editedByType:"Edited by",editors:[{id:"201848",title:"Dr.",name:"Alberto",middleName:"Adriano",surname:"Cavalheiro",slug:"alberto-cavalheiro",fullName:"Alberto Cavalheiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6306",title:"Additive Manufacturing of High-performance Metals and Alloys",subtitle:"Modeling and Optimization",isOpenForSubmission:!1,hash:"0e08cc35cef3caf389096ca4b999742f",slug:"additive-manufacturing-of-high-performance-metals-and-alloys-modeling-and-optimization",bookSignature:"Igor V. Shishkovsky",coverURL:"https://cdn.intechopen.com/books/images_new/6306.jpg",editedByType:"Edited by",editors:[{id:"178616",title:"Prof.",name:"Igor",middleName:"V.",surname:"Shishkovsky",slug:"igor-shishkovsky",fullName:"Igor Shishkovsky"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5759",title:"Lamination",subtitle:"Theory and Application",isOpenForSubmission:!1,hash:"9a4f81291f9d75ed83b1f4f5e0b56f36",slug:"lamination-theory-and-application",bookSignature:"Charles A. Osheku",coverURL:"https://cdn.intechopen.com/books/images_new/5759.jpg",editedByType:"Edited by",editors:[{id:"148660",title:"Dr.",name:"Charles",middleName:"Attah",surname:"Osheku",slug:"charles-osheku",fullName:"Charles Osheku"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3683",title:"Engineering the Future",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"engineering-the-future",bookSignature:"Laszlo Dudas",coverURL:"https://cdn.intechopen.com/books/images_new/3683.jpg",editedByType:"Edited by",editors:[{id:"135546",title:"Prof.",name:"Laszlo",middleName:null,surname:"Dudas",slug:"laszlo-dudas",fullName:"Laszlo Dudas"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:7,mostCitedChapters:[{id:"12376",doi:"10.5772/10380",title:"Digital Factory – Theory and Practice",slug:"digital-factory-theory-and-practice",totalDownloads:6635,totalCrossrefCites:5,totalDimensionsCites:9,book:{slug:"engineering-the-future",title:"Engineering the Future",fullTitle:"Engineering the Future"},signatures:"Milan Gregor and Stefan Medvecky",authors:null},{id:"59094",doi:"10.5772/intechopen.72973",title:"Structure and Properties of the Bulk Standard Samples and Cellular Energy Absorbers",slug:"structure-and-properties-of-the-bulk-standard-samples-and-cellular-energy-absorbers",totalDownloads:484,totalCrossrefCites:2,totalDimensionsCites:8,book:{slug:"additive-manufacturing-of-high-performance-metals-and-alloys-modeling-and-optimization",title:"Additive Manufacturing of High-performance Metals and Alloys",fullTitle:"Additive Manufacturing of High-performance Metals and Alloys - Modeling and Optimization"},signatures:"Pavel Kuznetcov, Anton Zhukov, Artem Deev, Vitaliy Bobyr and\nMikhail Staritcyn",authors:[{id:"223064",title:"D.Sc.",name:"Pavel",middleName:null,surname:"Kuznetcov",slug:"pavel-kuznetcov",fullName:"Pavel Kuznetcov"},{id:"227212",title:"Mr.",name:"Artem",middleName:null,surname:"Deev",slug:"artem-deev",fullName:"Artem Deev"},{id:"227213",title:"Mr.",name:"Vitaliy",middleName:null,surname:"Bobyr",slug:"vitaliy-bobyr",fullName:"Vitaliy Bobyr"},{id:"227215",title:"Mr.",name:"Anton",middleName:null,surname:"Zhukov",slug:"anton-zhukov",fullName:"Anton Zhukov"},{id:"227216",title:"Mr.",name:"Mikhail",middleName:null,surname:"Staritcyn",slug:"mikhail-staritcyn",fullName:"Mikhail Staritcyn"}]},{id:"60707",doi:"10.5772/intechopen.75832",title:"Processing Parameters for Selective Laser Sintering or Melting of Oxide Ceramics",slug:"processing-parameters-for-selective-laser-sintering-or-melting-of-oxide-ceramics",totalDownloads:1220,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"additive-manufacturing-of-high-performance-metals-and-alloys-modeling-and-optimization",title:"Additive Manufacturing of High-performance Metals and Alloys",fullTitle:"Additive Manufacturing of High-performance Metals and Alloys - Modeling and Optimization"},signatures:"Haidong Zhang and Saniya LeBlanc",authors:[{id:"213235",title:"Prof.",name:"Saniya",middleName:null,surname:"LeBlanc",slug:"saniya-leblanc",fullName:"Saniya LeBlanc"},{id:"213239",title:"Dr.",name:"Haidong",middleName:null,surname:"Zhang",slug:"haidong-zhang",fullName:"Haidong Zhang"}]}],mostDownloadedChaptersLast30Days:[{id:"60707",title:"Processing Parameters for Selective Laser Sintering or Melting of Oxide Ceramics",slug:"processing-parameters-for-selective-laser-sintering-or-melting-of-oxide-ceramics",totalDownloads:1224,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"additive-manufacturing-of-high-performance-metals-and-alloys-modeling-and-optimization",title:"Additive Manufacturing of High-performance Metals and Alloys",fullTitle:"Additive Manufacturing of High-performance Metals and Alloys - Modeling and Optimization"},signatures:"Haidong Zhang and Saniya LeBlanc",authors:[{id:"213235",title:"Prof.",name:"Saniya",middleName:null,surname:"LeBlanc",slug:"saniya-leblanc",fullName:"Saniya LeBlanc"},{id:"213239",title:"Dr.",name:"Haidong",middleName:null,surname:"Zhang",slug:"haidong-zhang",fullName:"Haidong Zhang"}]},{id:"71979",title:"Fillers in Wood Adhesives",slug:"fillers-in-wood-adhesives",totalDownloads:61,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"fillers",title:"Fillers",fullTitle:"Fillers"},signatures:"Abbas Hasan Faris",authors:[{id:"225720",title:"Dr.",name:"Abbas Hasan",middleName:null,surname:"Faris",slug:"abbas-hasan-faris",fullName:"Abbas Hasan Faris"}]},{id:"61155",title:"Powder Process with Photoresist for Ceramic Electronic Components",slug:"powder-process-with-photoresist-for-ceramic-electronic-components",totalDownloads:392,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"powder-technology",title:"Powder Technology",fullTitle:"Powder Technology"},signatures:"Minami Kaneko, Ken Saito and Fumio Uchikoba",authors:[{id:"157327",title:"Dr.",name:"Ken",middleName:null,surname:"Saito",slug:"ken-saito",fullName:"Ken Saito"},{id:"157328",title:"Dr.",name:"Minami",middleName:null,surname:"Kaneko",slug:"minami-kaneko",fullName:"Minami Kaneko"},{id:"157330",title:"Prof.",name:"Fumio",middleName:null,surname:"Uchikoba",slug:"fumio-uchikoba",fullName:"Fumio Uchikoba"}]},{id:"61394",title:"Introductory Chapter: Genome of Material for Combinatorial Design and Prototyping of Alloys",slug:"introductory-chapter-genome-of-material-for-combinatorial-design-and-prototyping-of-alloys",totalDownloads:501,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"additive-manufacturing-of-high-performance-metals-and-alloys-modeling-and-optimization",title:"Additive Manufacturing of High-performance Metals and Alloys",fullTitle:"Additive Manufacturing of High-performance Metals and Alloys - Modeling and Optimization"},signatures:"Igor Shishkovsky",authors:[{id:"174257",title:"Prof.",name:"Igor",middleName:null,surname:"Shishkovsky",slug:"igor-shishkovsky",fullName:"Igor Shishkovsky"}]},{id:"71582",title:"Towards Traditional Carbon Fillers: Biochar-Based Reinforced Plastic",slug:"towards-traditional-carbon-fillers-biochar-based-reinforced-plastic",totalDownloads:219,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"fillers",title:"Fillers",fullTitle:"Fillers"},signatures:"Mattia Bartoli, Mauro Giorcelli, Pravin Jagdale and Massimo Rovere",authors:[{id:"39628",title:"Dr.",name:"Mauro",middleName:null,surname:"Giorcelli",slug:"mauro-giorcelli",fullName:"Mauro Giorcelli"},{id:"188999",title:"Dr.",name:"Mattia",middleName:null,surname:"Bartoli",slug:"mattia-bartoli",fullName:"Mattia Bartoli"},{id:"319032",title:"Dr.",name:"Pravin",middleName:null,surname:"Jagdale",slug:"pravin-jagdale",fullName:"Pravin Jagdale"},{id:"319033",title:"Dr.",name:"Massimo",middleName:null,surname:"Rovere",slug:"massimo-rovere",fullName:"Massimo Rovere"}]},{id:"67918",title:"Ion Beam Experiments to Emulate Nuclear Fusion Environment on Structural Materials at CMAM",slug:"ion-beam-experiments-to-emulate-nuclear-fusion-environment-on-structural-materials-at-cmam",totalDownloads:426,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"ion-beam-techniques-and-applications",title:"Ion Beam Techniques and Applications",fullTitle:"Ion Beam Techniques and Applications"},signatures:"Marcelo Roldán, Patricia Galán, Fernando José Sánchez, Isabel García-Cortés, David Jiménez-Rey and Pilar Fernández",authors:null},{id:"70033",title:"Focused Ion Beam Tomography",slug:"focused-ion-beam-tomography",totalDownloads:308,totalCrossrefCites:1,totalDimensionsCites:0,book:{slug:"ion-beam-techniques-and-applications",title:"Ion Beam Techniques and Applications",fullTitle:"Ion Beam Techniques and Applications"},signatures:"Dilawar Hassan, Sidra Amin, Amber Rehana Solangi and Saima Q. Memon",authors:null},{id:"56424",title:"Bending of Laminated Composite Plates in Layerwise Theory",slug:"bending-of-laminated-composite-plates-in-layerwise-theory",totalDownloads:815,totalCrossrefCites:1,totalDimensionsCites:4,book:{slug:"lamination-theory-and-application",title:"Lamination",fullTitle:"Lamination - Theory and Application"},signatures:"Marina Rakočević",authors:[{id:"205043",title:"Prof.",name:"Marina",middleName:null,surname:"Rakocevic",slug:"marina-rakocevic",fullName:"Marina Rakocevic"}]},{id:"59643",title:"Introductory Chapter: Laminations - Theory and Applications",slug:"introductory-chapter-laminations-theory-and-applications",totalDownloads:756,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"lamination-theory-and-application",title:"Lamination",fullTitle:"Lamination - Theory and Application"},signatures:"Charles Attah Osheku",authors:[{id:"148660",title:"Dr.",name:"Charles",middleName:"Attah",surname:"Osheku",slug:"charles-osheku",fullName:"Charles Osheku"}]},{id:"71217",title:"Wood Adhesive Fillers Used during the Manufacture of Wood Panel Products",slug:"wood-adhesive-fillers-used-during-the-manufacture-of-wood-panel-products",totalDownloads:182,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"fillers",title:"Fillers",fullTitle:"Fillers"},signatures:"Long Cao, Xiaojian Zhou and Guanben Du",authors:[{id:"289729",title:"Dr.",name:"Xiaojian",middleName:null,surname:"Zhou",slug:"xiaojian-zhou",fullName:"Xiaojian Zhou"},{id:"291315",title:"Prof.",name:"Guanben",middleName:null,surname:"Du",slug:"guanben-du",fullName:"Guanben Du"},{id:"315365",title:"Dr.",name:"Long",middleName:null,surname:"Cao",slug:"long-cao",fullName:"Long Cao"}]}],onlineFirstChaptersFilter:{topicSlug:"technology-material-science",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/120516/miguel-monforte",hash:"",query:{},params:{id:"120516",slug:"miguel-monforte"},fullPath:"/profiles/120516/miguel-monforte",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()